US Pat. No. 10,136,881

LAPAROSCOPIC RETRACTOR DEVICES

Mayo Foundation for Medic...

1. A laparoscopic retractor device comprising:a handle;
an elongate shaft with a proximal end portion that is attached to the handle, the shaft extending from the handle and terminating at a distal free end portion, the shaft defining a first lumen;
an elongate shaft linkage disposed within the first lumen, the shaft linkage having a proximal end and a distal end;
a first actuator located at the handle and coupled to the proximal end of the shaft linkage;
an expandable portion including: (i) a distal end portion coupled to the distal free end portion of the shaft and (ii) a proximal end portion coupled to the distal end of the shaft linkage, wherein moving the actuator causes the expandable portion to move radially outward from the shaft or radially inward toward the shaft; and
a sheath with a lumen therethrough, at least a portion of the shaft being disposed within the lumen, the sheath being slidable distally and proximally along the shaft.

US Pat. No. 10,136,879

SYSTEM AND METHOD FOR NON-CONTACT ELECTRONIC ARTICULATION SENSING

Covidien LP, Mansfield, ...

1. A surgical instrument, comprising:a handle portion;
a body portion extending distally from the handle portion and defining a first longitudinal axis;
an articulation tool assembly defining a second longitudinal axis and having a proximal end, the articulation tool assembly disposed at a distal end of the body portion and being movable from a first position in which the second longitudinal axis is substantially aligned with the first longitudinal axis to at least a second position in which the second longitudinal axis is disposed at an angle with respect to the first longitudinal axis;
an articulation mechanism configured to articulate the articulation tool assembly, the articulation mechanism including:
an articulation link mechanically engaged to the articulation tool assembly; and
an articulation knob mechanically engaged to the articulation link, wherein rotational motion of the articulation knob is translated into articulation movement of the articulation tool assembly through the articulation link; and
an articulation sensor assembly including:
a photo sensor disposed in spaced relation to the articulation link and configured to detect light reflected from the articulation link, the photo sensor configured to transmit a sensor signal; and
a microcontroller configured to determine an articulation angle of the articulation tool assembly based on the sensor signal.

US Pat. No. 10,136,878

AUTOMATIC DEVICE AND KIT FOR INSERTING A CANNULA TO A PREDETERMINED DEPTH WITHIN A BONE, IRRESPECTIVE OF THE THICKNESS OF THE TISSUE ABOVE THE BONE

WAISMED LTD., Herzliya (...

1. An automatic device for causing penetration of a stylet and cannula to a predefined depth ? within a bone, said depth ? being irrespective of a thickness of tissue above the bone, said device comprising:a) a trigger unit for activating the device;
b) a barrel;
c) a probe unit positioned within said barrel which is driven by a secondary spring, said probe unit comprises one or more probing needles at a distal end, and an anvil at a proximal end for defining an end of movement location for a hammer unit;
d) said hammer unit which is driven by a main spring and comprises a stylet which is longer than said one or more probing needles at its distal end, a core at its proximal end, and a piston between said core and stylet;
e) a cannula within which said stylet is inserted; and
f) one or more grasping units;
wherein when said hammer unit is positioned at said end of movement location, a tip of said stylet is located a distance ? farther in a distal direction from respective ends of said probing needles,
wherein said secondary spring, when released in response to activation of said trigger unit, is configured to push said one or more probing needles of said probe unit toward the bone, up to a point of contact with a surface of the bone,
wherein said one or more grasping units are configured to grasp the anvil of said probe unit, upon contact between said one or more probing needles and the bone surface,
wherein said main spring, when released in response to the activation of said trigger unit, is configured to push said hammer unit to said end of movement location and thereby cause penetration of said cannula to a depth of ? within the bone.

US Pat. No. 10,136,877

ULTRASOUND DIAGNOSIS APPARATUS AND IMAGE PROCESSING APPARATUS

Toshiba Medical Systems C...

1. An ultrasound diagnosis apparatus, comprising:processing circuitry configured to
generate three-dimensional image data based on reflected-wave data received by an ultrasound probe,
generate a two-dimensional tomographic image using the three-dimensional image data,
set a value of an image quality adjusting parameter used for generating a virtual endoscopic image so that a position of an internal wall of a lumen in the three-dimensional image data matches a corresponding position of the internal wall of the lumen in the two-dimensional tomographic image or so that a distance between two points on opposing sides of the internal wall of the lumen in the three-dimensional image data is equal to a corresponding distance between two points set in the two-dimensional tomographic image;
generate the virtual endoscopic image by projecting an inside of the lumen from a predetermined viewpoint and using the value of the set image quality adjusting parameter; and
cause a predetermined display to display the virtual endoscopic image.

US Pat. No. 10,136,875

ULTRASONIC DIAGNOSTIC APPARATUS AND ULTRASONIC DIAGNOSTIC METHOD

Konica Minolta, Inc., To...

1. An ultrasonic diagnostic apparatus that decides a type of a tumor contained in a specimen, the apparatus comprising:an image forming unit that forms an ultrasonic image corresponding to an echo signal received from the specimen after administration of a contrast medium;
a feature value calculating unit that classifies each of a plurality of pixel regions contained in a tumor region including the tumor in the ultrasonic image into a low-luminance region, or a high-luminance region having higher luminance than the luminance of the low-luminance region, and calculates, based on a difference between a variance at a position of the low-luminance region and a variance at a position of the high-luminance region, a ring level indicating a degree of a ring shape of an image of the tumor region, the ring shape in which a luminance value of a central portion is lower than a luminance value of a peripheral portion surrounding the central portion; and
a type deciding unit that decides the type of the tumor based on the ring level.

US Pat. No. 10,136,873

RADIOGRAPHIC IMAGE PROCESSING DEVICE, METHOD, AND RECORDING MEDIUM

FUJIFILM Corporation, Mi...

1. A radiographic image processing device comprising:at least one hardware processor configured to implement:
a frequency decomposition unit for performing frequency decomposition for a first radiographic image which is captured by irradiating a subject with radiation and acquiring a plurality of band images indicating a plurality of frequency components of the first radiographic image;
a scattered radiation removal unit for calculating a scattered radiation component that is caused by the subject and is included in a second radiographic image of the subject which has a linear relationship with an amount of radiation, using the second radiographic image, and removing the scattered radiation component from the second radiographic image to acquire a scattered-radiation-removed radiographic image;
a conversion function determination unit for determining a conversion function for converting at least one of the band images according to the scattered radiation component included in the second radiographic image;
a conversion unit for converting the at least one band image, using the conversion function, and generating a converted band image; and
a reconstruction unit for reconstructing the scattered-radiation-removed radiographic image and the converted band image to acquire a processed radiographic image,
wherein the first radiographic image has a pixel value that has a linear relationship with a logarithmic amount of radiation, and
wherein the second radiographic image is obtained by performing inverse logarithmic conversion for the first radiographic image.

US Pat. No. 10,136,872

DETERMINATION OF AN X-RAY IMAGE DATA RECORD OF A MOVING TARGET LOCATION

1. A method for determining an x-ray image data record of a target location of a patient subjected to a movement using an x-ray device, the method comprising:recording a plurality of component images of the target location using an image exposure time;
registering the plurality of component images with one another;
determining one or more quality values related to the movement of the target for each component image of the plurality of component images, the one or more quality values including at least a motion speed calculated as a comparison between a spread function of at least two or more of the plurality of component images and a reference spread function of the x-ray device;
selecting as a function of the one or more quality values a contribution of one or more basic images of the plurality of component images; and
combining the one or more component images into the x-ray image data record as a function of the selected contribution of the one or more component images.

US Pat. No. 10,136,871

EXTREMITY IMAGING FOR ANIMALS

Carestream Health, Inc., ...

1. An apparatus for radiographic imaging of an animal, the apparatus comprising:a support base having a top surface to support a four legged animal standing thereon;
a moveable x-ray source disposed within a source housing and mechanically attached to the support base; and
a digital radiographic detector mechanically attached to the support base, wherein the source housing and the detector extend upward substantially perpendicular to, and above, the top surface of the support base, and wherein the x-ray source and the detector are configured to capture a radiographic image of at least one foreleg or hind leg of the standing animal,
wherein the source and the detector are attached to separate, concentric, moveable portions of the top surface of the support base, each of the moveable portions of the top surface of the support base comprising a ring shape coplanar with a plane of the top surface of the support base.

US Pat. No. 10,136,870

EXTREMITY IMAGING FOR ANIMALS

Carestream Health, Inc., ...

1. An apparatus for radiographic imaging of an animal, the apparatus comprising:a floor to support an animal standing on its legs;
a moveable x-ray source disposed above a surface of the floor within a source housing and mechanically attached to a rotation mechanism; and
a digital radiographic detector disposed below the surface of the floor and mechanically attached to the rotation mechanism, wherein the source housing remains stationary, and wherein the x-ray source and the detector are configured to revolve around at least one extremity of the animal to capture at least one radiographic image thereof.

US Pat. No. 10,136,868

FAST DUAL ENERGY FOR GENERAL RADIOGRAPHY

General Electric Company,...

1. A system, comprising:an X-ray source configured to generate X-rays directed toward an object, wherein the X-ray source is to: (i) generate a first energy X-ray pulse, (ii) switch to generate a second energy X-ray pulse, and (iii) switch back to generate another first energy X-ray pulse, wherein the second energy X-ray pulse is associated with higher voltage level as compared to the first energy X-ray pulses;
a detector associated with multiple image pixels, the detector including, for each pixel:
an X-ray sensitive element to receive X-rays,
a first storage element and associated switch to capture information associated with the first energy X-ray pulses, and
a second storage element and associated switch to capture information associated with the second energy X-ray pulse; and
a controller to synchronize the X-ray source and detector.

US Pat. No. 10,136,867

RADIOLOGICAL IMAGING SYSTEM WITH IMPROVED INTERNAL MOVEMENT

IMAGINALIS SRL, Sesto Fi...

1. A radiological imaging system, comprising:a bed;
a load-bearing structure connected to the bed and configured to support the bed; and
a gantry connected to the load-bearing structure, the gantry defining a main axis of expansion, the gantry having a source configured to emit radiation, a detector with a sensitive surface configured to detect the radiation, an internal inner guide configured to rotate the detector around the main axis of expansion defining an inner sliding trajectory, and an internal outer guide configured to rotate the source around the main axis of expansion defining an outer sliding trajectory, wherein the distance from the source to the main axis of expansion is greater than the distance from the detector to the main axis of expansion, and the gantry including a casing housing the source, the detector, the internal inner guide, and the internal outer guide,
wherein the casing includes a fixed arched module, a first mobile arched module, and a second mobile arched module.

US Pat. No. 10,136,866

RADIATION IRRADIATION DEVICE

FUJIFILM Corporation, To...

1. A radiation irradiation device comprising:a radiation generation unit that generates radiation;
an arm part having one end to which the radiation generation unit is attached;
a support member having one end to which the other end of the arm part is connected so as to be rotationally movable;
a body part to which the other end of the support member is connected; and
a leg part on which the body part is placed,
wherein in a case where a side toward which the arm part extends from the body part during use of the device is defined as a front side, the leg part includes a first caster which is provided on the front side of a bottom surface of the leg part and to which a rotating shaft of a wheel is revolvably supported and a second caster which is provided on a rear side of the bottom surface of the leg part and to which a rotating shaft of a wheel is revolvably supported, and
wherein a diameter of the wheel of the second caster is greater than a diameter of the wheel of the first caster, and a gravity center position of the entire device is closer to the second caster side than a center between the first caster and the second caster in a state where the arm part is rotationally moved until the radiation generation unit is located at a vertically lowermost position.

US Pat. No. 10,136,864

X-RAY COLLIMATOR SIZE AND POSITION ADJUSTMENT BASED ON PRE-SHOT

KONINKLIJKE PHILIPS N.V.,...

1. An X-ray apparatus for image acquisition, comprising:an X-ray source configured to generate X-ray radiation for image acquisition of an object;
a collimator comprising at least one moveable shutter, the collimator being configured to collimate the X-ray radiation into a radiation cone, said radiation cone irradiating the object at a region of interest when acquiring an image;
a portable radiation detector configured to register the X-ray radiation after passage through the object; and
a field-of-view corrector configured to receive, in a pre-shot imaging phase, a scout image (SI) acquired by the portable radiation detector with a tentative setting of the collimator, the pre-shot imaging phase causing a low dosage radiation cone to impinge on the portable radiation detector, the low dosage radiation cone having in an image plane of the portable radiation detector a first cross section being smaller than a surface area of the portable radiation detector,
the field-of-view corrector being further configured to use said scout image to establish field-of-view correction information for a subsequent imaging phase, the field of view correction information including collimation correction information for determining a corrected setting of the collimator,
wherein, in the subsequent imaging phase, the corrected setting of the collimator results in a high dosage radiation cone impinging on the portable radiation detector, the high dosage radiation cone providing a higher dosage of radiation than the low dosage radiation cone, and the high dosage radiation cone having, in the image plane of the portable radiation detector, a second cross section that is larger than the first cross section and the high dosage radiation cone i) being essentially coextensive with the surface area of the portable radiation detector or ii) being a symmetric enlargement of the first cross section and extending in its entirety within the surface area of the portable radiation detector.

US Pat. No. 10,136,862

METHOD OF SONIFYING BRAIN ELECTRICAL ACTIVITY

The Board of Trustees of ...

1. A method of sonifying brain signals using a digital processor system that comprises at least one processing unit, the method comprising:filtering, with a front-end module coupled to the digital processor system, a continuous time-domain sensor signal representing brain activity of a subject obtained from at least one sensor in order to generate a filtered continuous time-domain sensor signal;
producing a continuous time-domain signal representing the brain activity of the subject from the filtered continuous time-domain sensor signal using the digital processor system, the continuous time-domain signal having a time varying signal value;
concurrently generating a plurality of continuously time-varying acoustic parameters from the continuous time-domain signal using the digital processor system, the plurality of continuously time-varying acoustic parameters including a vowel-control parameter, an intensity-control parameter, and a pitch-control parameter, wherein at least three of the parameters in the plurality of continuously time-varying acoustic parameters are continuously modulated in proportion with at least the continuous time varying signal value of the time-domain signal during concurrent generation;
driving, with the digital processor system, an audio synthesizer using the concurrently generated plurality of continuously time-varying acoustic parameters, including the vowel-control parameter, the intensity-control parameter, and the pitch-control parameter, to produce a representation of an acoustic signal corresponding to the brain activity of the subject represented by the continuous time-domain signal;
performing continuous audio playback of the representation of the acoustic signal using the digital processor system, wherein performing the continuous audio playback comprises audibly providing, with at least one speaker, the representation of the acoustic signal for diagnosis and/or treatment of a condition of the subject.

US Pat. No. 10,136,859

SYSTEM AND METHOD FOR OUTPATIENT MANAGEMENT OF CHRONIC DISEASE

1. An outpatient ambulatory patient worn apparatus for managing chronic lung disease comprising:a plurality of sensors configured to be worn by a patient and to measure a plurality of physiological data, said plurality of sensors including at least one oximeter, a respiratory rate sensor, and at least one activity or motion sensor, at least said oximeter, said at least one oximeter, said respiratory rate sensor, and said at least one activity or motion sensor continuously operative to measure said plurality of physiological data in an outpatient setting during activities of daily living comprising rest, exertion, and sleep;
a central monitoring unit (CMU) communicatively coupled to said plurality of sensors and to an interface device, said CMU comprising a computer, and said CMU to be worn by the patient in said outpatient setting during activities of daily living, said CMU programmed to record concurrently a set of time stamped primary data comprising measurement data from each of said plurality of sensors to a non-volatile memory at a predetermined interval for one or more epochs of time, and to categorize at an acquisition rate or some multiple of the acquisition rate each recorded measurement of each of said plurality of sensors stored in said set of time stamped primary data by a predominate activity type to generate a set of activity type stamped data, said predominate activity type selected from a plurality of activity types including rest, exertion, and sleep; and
a generate report process running on said CMU to provide at least one or more reports in real time including at least an indication or determination of whether a chronic lung disease treatment is needed by the patient based on said set of activity type stamped data.

US Pat. No. 10,136,858

METHOD FOR INSPECTING PRESSURE PULSE WAVE SENSOR AND METHOD FOR MANUFACTURING PRESSURE PULSE WAVE SENSOR

OMRON HEALTHCARE Co., Ltd...

1. A method for inspecting a pressure pulse wave sensor which includes a sensor chip and a substrate, the sensor chip including a pressure-sensitive element array constituted by a plurality of pressure-sensitive elements arranged in one direction, the sensor chip put into use so that a pressure-sensitive face of the sensor chip where the pressure-sensitive element array is formed is pressed against a body surface of a living body in a state in which the one direction intersects with a traveling direction of an artery of the living body, the sensor chip fixed to the substrate, whereinthe substrate includes a through hole and a substrate-side terminal portion,
the sensor chip includes a recess which is recessed in a direction perpendicular to the pressure-sensitive face and on an opposite side to the pressure-sensitive face, and the pressure-sensitive element array is formed on the pressure-sensitive face in a portion of the sensor chip whose thickness is reduced in the perpendicular direction due to the recess, and
the sensor chip further includes a chip-side terminal portion which is electrically connected to the pressure-sensitive element array and which is provided at one or each of opposite ends of the pressure-sensitive element array extending in the one direction,
the method comprising:
bonding and fixing the sensor chip onto the substrate so that the recess communicates with atmospheric air through only the through hole of the substrate;
connecting the substrate-side terminal portion of the substrate to which the sensor chip is bonded and fixed, and the chip-side terminal portion through an electrically conductive member;
covering the electrically conductive member with a protective member; and
performing characteristic evaluation about a variation among the plurality of pressure-sensitive elements of the sensor chip, after covering the electrically conductive member with the protective member, based on a signal outputted from the substrate-side terminal portion in a state in which air is sucked through the through hole of the substrate to thereby apply negative pressure to the pressure-sensitive face.

US Pat. No. 10,136,856

WEARABLE RESPIRATION MEASUREMENTS SYSTEM

Facense Ltd., Kiryat Tiv...

1. A system configured to collect thermal measurements related to respiration, comprising:a frame configured to be worn on a user's head; and
at least one thermal camera that is physically coupled to the frame; wherein the frame is configured to hold the at least one thermal camera less than 15 cm away from the user's face, such that the at least one thermal camera does not occlude any of the user's mouth and upper lip;
wherein the at least one thermal camera is configured to take thermal measurements of: a portion of the right side of the user's upper lip (THROI1), a portion of the left side of the user's upper lip (THROI2), and a portion of the user's mouth (THROI3).

US Pat. No. 10,136,855

AUTOMATIC ADJUSTMENT OF HELMET PARAMETERS BASED ON A CATEGORY OF PLAY

INTERNATIONAL BUSINESS MA...

1. A method for automatic adjustment of helmet parameters based on a category of play, the method comprising:monitoring a plurality of sensors in a helmet;
determining the category of play for a user of the helmet based on data received from the plurality of sensors; and
automatically adjusting parameters of the helmet based on the category of play, wherein the parameters include at least one of a stiffness, a size and a shape of a padding of the helmet,
wherein a type of an adjustment and an amount of the adjustment are determined based on a model of expected risks for the category of play for the user.

US Pat. No. 10,136,854

STRETCHABLE THERMOELECTRIC MATERIAL AND THERMOELECTRIC DEVICE INCLUDING THE SAME

Samsung Electronics Co., ...

1. A thermoelectric material, comprising:a stretchable polymer; and
a thermoelectric structure and electrically conductive material that are mixed together in the stretchable polymer, the thermoelectric structure including a carbon-containing material, wherein
the carbon-containing material includes carbon nanotubes,
the carbon nanotubes are arranged in an array, and
lengths of the carbon nanotubes are parallel to each other.

US Pat. No. 10,136,853

CONTACTLESS SLEEP DISORDER SCREENING SYSTEM

KONINKLIJKE PHILIPS N.V.,...

1. A system configured to monitor a sleep session of a patient without making physical contact with the patient, the system comprising:a sound sensor configured to generate output signals that convey information related to sound originating from the patient in a sleeping environment;
a movement sensor comprising:
a light source configured to project a structured light pattern onto the patient which deforms when the patient moves; and
a detector configured to receive light reflected from the patient, the detector configured to generate output signals that convey information related to changes in the structured light pattern projected onto the patient caused by movement of the patient; and
one or more hardware processors configured by machine-readable instructions to:
receive and store data relating to the sound originating from the patient based on the information conveyed by the output signals from the sound sensor,
determine movement of the patient based on (1) a distance between the light source and the detector, and (2) a change in angle of reflected light from the structured light pattern received from an individual moving point on the patient, wherein images derived from the information related to changes in the structured light pattern are construed wherein an indication of motion vectors is provided, wherein the motion vectors indicate a direction and an amplitude of the movement of the patient, wherein the motion vectors facilitate segmentation of one or more body parts, and wherein information related to a mouth movement is determined based on the segmentation of the one or more body parts, and
determine a sleep disorder diagnosis based on the sound originating from the patient and the movement of the patient, wherein the one or more hardware processors are configured to determine parasomnia Bruxism based on the determined mouth movement.

US Pat. No. 10,136,852

DETECTING AN ALLERGIC REACTION FROM NASAL TEMPERATURES

Facense Ltd., Kiryat Tiv...

1. A system configured to detect allergic reaction, comprising:an inward-facing head-mounted thermal camera (CAM) configured to take thermal measurements of a region on the nose (THN) of a user; and
a computer configured to: generate feature values based on THN, and utilize a machine learning-based model to detect an allergic reaction of the user based on the feature values; wherein the machine learning-based model was trained based on previous THN taken during different days.

US Pat. No. 10,136,851

INTEGRATED DEVICE TO MEASURE VARIATIONS IN NEUROMUSCULAR CONTROL WHEN TRACING DEFINED TARGET PATTERNS AND A SYSTEM AND METHOD OF USING THE INTEGRATED DEVICE

1. A device for measuring variations in neuromuscular control of a user, comprising:an integrated device, including:
a computing device configured to be held by the user;
a pointing device attached to, or integrated with the computing device, the pointing device including an end portion;
the computing device configured to detect three-dimensional movement data of the integrated device relative to a particular pattern predefined in the computing device while the user is tracing the pattern;
wherein the pointing device is configured for the end portion to be pointed at said pattern at a predefined distance from said pattern to trace said pattern, without the end portion physically touching the pattern.

US Pat. No. 10,136,850

BIOLOGICAL STATE ESTIMATION DEVICE, BIOLOGICAL STATE ESTIMATION SYSTEM, AND COMPUTER PROGRAM

Delta Tooling Co., Ltd., ...

1. A biological body state estimation device for estimating a state of fatigue of a person using a biological signal obtained from an upper body of the person, comprising:an air pack configured to be brought into contact with a back part of the person and whose pressure has a pressure fluctuation that fluctuates with fluctuation in the aorta caused by movement of the heart, the air pack being further configured to output the pressure fluctuation as the biological signal; and
circuitry in electronic communication with the air pack and configured to
receive the biological signal from the air pack;
analyze the biological signal, and acquire and sort a homeostatic function level of the person at a predetermined point of time into a plurality of stages;
plot the homeostatic function level in a time series by taking each stage of the homeostatic function level on a vertical axis and time on a lateral axis and display a fluctuation degree of the homeostatic function level on a display circuit as a graph; and
determine the state of fatigue from the homeostatic function level;
wherein the circuitry is configured to analyze the biological signal and acquire and sort the homeostatic function by:
acquiring a frequency of the biological signal;
conducting a movement calculation to acquire a slope of the frequency for each predetermined time window set with a predetermined overlapped time from the frequency of the biological signal and acquiring a time-series waveform of the slope of the frequency obtained for each time window;
differentiating the time-series waveform of the slope of the frequency;
integrating the time-series waveform of the slope of the frequency;
acquiring a rectangular wave from an increase/decrease of the time-series waveform of the slope of the frequency;
acquiring a describing function and a describing function amplitude value between the time-series waveform of the slope of the frequency in an arbitrarily set first time zone and the time-series waveform of the slope of the frequency in a second time zone after the first time zone;
applying absolute value processing to the time-series waveform of the respective slopes of the frequency by using a time-series waveform of the frequency of the biological signal using a maximum value of the time-series waveform of the biological signal and a time-series waveform of the frequency of the biological signal using a zero-crossing point where the sign of the time-series waveform of the biological signal is switched; and
acquiring the stage of the homeostatic function level by determining whether at least two indices indicate a characteristic change, wherein the at least two indices have the characteristic change according to said each stage of the homeostatic function level and are chosen independently for said each stage of the homeostatic function level, the at least two indices comprising at least two of the slope of the frequency, the differential value, the integral value, the sign of the rectangular wave, the describing function amplitude value, and two absolute values of the time-series waveform of the slope of the frequency.

US Pat. No. 10,136,848

DEVICE AND SYSTEM OF BLOOD COLLECTION, AND METHOD THEREOF

Winnoz Technology, Inc., ...

1. A device for collecting a blood sample, comprising:a collection unit comprising:
a top window;
a top surface;
a channel communicated with the top window;
at least one capillary tube having a top end adjacent to the top window;
wherein a distance between the top end of the at least one capillary tube and the top surface of the collection unit is in a range of 1.0 mm to 5.0 mm, such that the top end of the at least one capillary tube is used to contact with a blood drop from a puncture to continuously draw the blood flowing inside or along the at least one capillary tube into a storage unit by disrupting a surface tension of the blood drop, and
a vacuum connector communicated with the channel, extended outwardly from the collection unit, and connected to a pressure control unit to remove air from the channel and create an alternating negative pressure in the channel; and
the storage unit disposed under the collection unit.

US Pat. No. 10,136,847

MITIGATING SINGLE POINT FAILURE OF DEVICES IN AN ANALYTE MONITORING SYSTEM AND METHODS THEREOF

Abbott Diabetes Care Inc....

1. A computer-implemented method for mitigating single point failure of at least one device in an analyte monitoring system, comprising:providing a request, from a first device to a second device, that a functionality check of one or more components of a third device be performed, wherein the functionality check includes communicating, from the third device to the second device, data related to results of the functionality check;
receiving, at the first device, the data related to the results of the functionality check from the second device;
determining, by the first device, that the one or more components of the third device is not functioning in accordance with at least one predetermined criterion; and
providing, to the second device, a request from the first device that an alarm function be initiated to alert a user that the one or more components of the third device is not functioning in accordance with the at least one predetermined criterion.

US Pat. No. 10,136,846

MICRONEEDLE ARRAYS FOR BIOSENSING AND DRUG DELIVERY

The Regents of the Univer...

1. An analyte-selective sensor device, comprising:a substrate that includes at least one microneedle with a hollowed interior, wherein the at least one microneedle comprises an interior wall with an opening to the hollowed interior;
an electrode comprising a probe, wherein the probe is disposed inside the hollowed interior and spaced away from the interior wall, wherein the electrode is functionalized by a coating comprising an enzyme-functionalized coating or an ion-selective coating over at least the probe to interact with an analyte to produce an electrical signal; and
a wire electrically coupled to the probe operable to transfer the electrical signal.

US Pat. No. 10,136,845

DEVICES, SYSTEMS, AND METHODS ASSOCIATED WITH ANALYTE MONITORING DEVICES AND DEVICES INCORPORATING THE SAME

ABBOTT DIABETES CARE INC....

1. An apparatus for receiving analyte data from an in vivo analyte sensing device, comprising:a housing;
a display mounted on the housing;
an input component;
a test strip port;
a processor mounted in the housing; and
a memory storing instructions which, when executed by the processor, cause the processor to:
navigate from a current user interface screen on the display to a home screen in response to a press of the input component by a user unless a test strip is in the test strip port and a test strip result has not yet been computed;
cause display of the home screen, wherein the home screen includes an indication of the time remaining until the in vivo analyte sensing device expires; and
cause display of received analyte information,
wherein the instructions, when executed by the processor, cause the processor to render inactive the press of the input component by the user to navigate from the current user interface screen on the display to the home screen if the test strip is in the test strip port and the test strip result has not yet been computed.

US Pat. No. 10,136,843

AUDIOLOGIC TEST APPARATUS, SYSTEM AND RELATED METHOD

Natus Medical Incorporate...

12. An audiologic test system for performing an audiologic test, the audiologic test system comprising:an audiologic test apparatus comprising:
a housing;
a processing unit in the housing;
a tone generator connected to the processing unit, the tone generator being instructed by the processing unit to generate a first electrical signal and a second electrical signal;
a probe interface for connecting the audiologic test apparatus to a test probe; and
a pump module having a pressure sensor connected to the processing unit;
a first speaker connected with the audiologic test apparatus; and
a first microphone connected with the audiologic test apparatus;
wherein the processing unit is configured to:
provide a first signal with a first primary frequency component at a first primary frequency through the first speaker, the first electrical signal is representative of the first signal;
obtain a first response signal from the probe interface through the first microphone;
determine if a first insertion criterion is satisfied based on the first signal and the first response signal;
modify pressure in an ear canal;
detect a pressure response utilizing the pressure sensor;
determine if a second insertion criterion is satisfied; and
initiate the audiologic test to examine at least one part of an auditory system of a user if the first insertion criteria and the second insertion criterion are satisfied, the audiologic test includes generation of the second signal with a second primary frequency component at a second primary frequency, the second electrical signal is representative of the second signal;
wherein the audiologic test apparatus is configured to receive an input generated using the pressure sensor and determines if the second insertion criterion is satisfied based on the input thereby indicating proper insertion of the test probe in the ear canal to examine the at least one part of the auditory system of the user.

US Pat. No. 10,136,842

FOOTWEAR APPARATUS WITH TECHNIQUE FEEDBACK

1. A footwear apparatus comprising:a sensor in the footwear apparatus positioned to monitor an activity technique of a user when the footwear apparatus is joined with a foot of the user, and
a feedback generator arranged to produce a haptic communication to the user in response to detecting a pattern in the activity technique, the haptic communication arranged to cause at least some discomfort to the user, wherein the pattern includes a pronation element.

US Pat. No. 10,136,841

MULTI-FUNCTIONAL SMART MOBILITY AID DEVICES AND METHODS OF USE

CAN Mobilities, Inc., Sa...

1. A multifunctional smart cane, comprising:a handle adapted to be gripped by a hand of a user;
a body having a base on one end and coupled to the handle on the other;
a light operable by a light sensor;
a display built into the handle wherein the display is visible to the user while gripping the handle;
one or more activity tracking components carried by the smart cane for collecting information about the user's daily activity;
an electronic memory for storing the collected information about the user's daily activity; and
one or more electronic communication components to transmit the user's daily activity from the electronic memory in the smart cane to another electronic device.

US Pat. No. 10,136,839

AIRWAY ADAPTOR

NIHON KOHDEN CORPORATION,...

1. An airway adaptor adapted to be attached to a mask, the mask adapted to be attached to a face of a living body, the airway adaptor comprising:an airway case;
an expired gas guiding portion which is connected to the airway case to introduce a respiratory gas to the airway case;
a partition wall;
an elongated first passage adapted to introduce the respiratory gas from the expired gas guiding portion to the airway case; and
an elongated second passage adapted to discharge the respiratory gas from the elongated first passage, which has been introduced to the airway case and returned in the airway case without being communicated with the expired gas guiding portion, to outside of the airway case,
wherein the partition wall partitions the elongated first passage and the elongated second passage such that a portion of the elongated first passage is parallel to a portion of the elongated second passage,
wherein the respiratory gas in the portion of the elongated first passage flows in a first direction and the respiratory gas in the portion of the elongated second passage flows in a second direction opposite and in reverse with respect to the first direction,
wherein the airway case includes a respiratory gas flow path through which the respiratory gas passes, the respiratory gas flow path including:
the elongated first passage in which the respiratory gas flows in the first direction; and
the elongated second passage in which the respiratory gas flows in the second direction opposite and in reverse with respect to the first direction,
the elongated first passage and the elongated second passage being connected to each other in an opening of the airway case, and
wherein, when the mask is attached to the face of the living body, at least a part of the airway case that includes the opening in which the elongated first passage and the elongated second passage are connected is projected to an outside of a shell of the mask.

US Pat. No. 10,136,838

PERSONAL SPIROMETER

PMD Healthcare, Lansdale...

1. A hand-held spirometer for correlating test results with a medical condition, said spirometer comprising:a portable housing having handles configured for said user to grip said handles to hold said housing during use;
a display on a surface of said housing;
an airflow tube through said housing;
one or more air flow sensors associated with said airflow tube;
a processor in said housing;
memory operatively connected to said processor and configured with instructions to instruct the processor to perform the following steps:
determining and recording sequential lung performance values based on data from said air flow sensors over a period;
recording user data during said period, said user data comprising at least medical compliance;
correlating said sequential lung performance values and said user data over said period; and
displaying a relationship between said sequential lung performance data and said medical compliance over said period on said display; and wherein said relationship on said display comprises a plot of lung performance per increment of time during said period with an indication of medical compliance for each said increment of time during said period.

US Pat. No. 10,136,837

DEVICE AND METHOD FOR THE ANALYSIS OF THE AIR EXHALED BY A SUBJECT IN ORDER TO MEASURE THE BASAL METABOLISM THEREOF

COSMED S.r.l., Roma (IT)...

1. Device for the analysis of the air exhaled by a subject in order to measure basal metabolism of the subject, the device comprising:a main line, for passage of a sampling flow of the air exhaled by the subject,
a suction pump having a substantially constant flow rate, said pump being arranged downstream of the main line, for drawing said sampling air flow into the main line,
a mixing mini-chamber interposed in the main line upstream of the suction pump for accumulating or mixing with each other a plurality of air sampling flows exhaled by the subject within a number of respiratory cycles,
a by-pass line arranged in parallel to the mixing mini-chamber through which the air flow can flow without passing through said mixing mini-chamber,
a by-pass valve interposed in the main line downstream of the mixing mini-chamber and selectively displaceable in two different positions for causing the airflow through the main line to flow either through the mixing mini-chamber or through said by-pass line,
first sensor means for sensing the oxygen concentration and second sensor means for sensing the carbon dioxide concentration, said first and second sensor means being arranged in the main line between said by-pass valve and the suction pump, for measuring the oxygen concentration and the carbon dioxide concentration within the air flow through the main line downstream of the mixing mini-chamber,
a first switching valve for switching the suction inlet of the suction pump between a condition of connection to said first and second sensor means and a condition in which this connection is interrupted,
flow measuring means for detecting the flow rate of the air inhaled or exhaled by the subject, and
an electronic controller configured for:
receiving and processing signals emitted by said first sensor means of the oxygen concentration, by said second sensor means of the carbon dioxide concentration and by said flow measuring means so as to obtain a measurement of oxygen consumption and carbon dioxide production by the subject within a number of respiratory cycles,
wherein said device further comprises:
a first inlet connector connected to a system for taking a flow of air exhaled by a subject who breathes spontaneously,
a second inlet connector connected through a sampling line to a system for taking a flow of air exhaled by a subject undergoing assisted pulmonary ventilation,
a selection valve interposed in the main line upstream of the mixing mini-chamber for selectively connecting said first connector or said second connector to said main line,
said selection valve having an outlet connected to the main line, a first inlet connected to said first connector and the second inlet for connection to said second connector,
a calibration line, which receives a calibration flow, to be used for calibrating said first and second sensor means for sensing the oxygen concentration and the carbon dioxide concentration,
a second switching valve adapted to be switched between a sampling state and a calibration state, said switching valve being controlled by said electronic controller for selectively connecting said second inlet of said selection valve to said sampling line connected to said second connector or to said calibration line,
a plurality of selector valves distributed in series along said calibration line for selectively connecting the calibration line each time to one only among a plurality of auxiliary lines adapted to provide respective calibration data,
said electronic controller being configured so that, during normal operation of the device, the selection valve is switched for feeding to the main line either a sampling flow of the air exhaled by a subject who breathes spontaneously or by a subject which undergoes assisted pulmonary ventilation, said by-pass valve being in a position causing the airflow to pass through said mixing mini-chamber so that said electronic controller is able to perform said processing in order to obtain said measurement of the oxygen consumption and the carbon dioxide production by the subject within a number of respiratory cycles,
said electronic controller being further programmed for automatically starting, upon switching on the device, a self-calibration stage of the device in which:
the second switching valve communicates said second connector of said selection valve to said calibration line while the selection valve communicates its second inlet to said main line, so that the main line enters into communication with said calibration line,
said electronic controller being configured so that in said self-calibration stage the by-pass valve is in a position which causes said sampling flow of the air exhaled by the subject to flow through said by-pass line, without passing through said mixing mini-chamber, whereby the self-calibration stage can be carried out immediately on the basis of the flow coming from said calibration line, without requiring a filling of said mixing mini-chamber.

US Pat. No. 10,136,834

NEURONAL RESONANCE MAGNETIC RESONANCE IMAGING METHOD

KOREA ADVANCED INSTITUTE ...

1. A magnetic resonance signal processing method for detecting a magnetic field oscillation signal, the method comprising:obtaining N pieces of MRI (magnetic resonance imaging) data by repeating a step of obtaining an MRI data with an MRI scheme using a gradient magnetic field pattern N number of times while changing relative phases between the gradient magnetic field pattern and the magnetic field oscillation signal; and
calculating a value related to an energy of a predetermined frequency component of an arranged signal produced by arranging the obtained N pieces of MRI data on a time-axis according to the relative phases,
wherein the N pieces of MRI data are K-space data or the N pieces of MRI data are MRI image data.

US Pat. No. 10,136,833

IMPLANTABLE RADIO-FREQUENCY SENSOR

ZOLL MEDICAL ISRAEL, LTD....

1. A diagnostic apparatus, comprising:a sealed case, comprising a biocompatible material and configured for implantation within a body;
a first antenna and a second antenna, each antenna configured to:
be implanted in the body in proximity to a target tissue,
generate and transmit radio frequency (RF) electromagnetic waves through the target tissue to the other antenna, and
output a signal in response to RF waves received from the other antenna; and
processing circuitry, which is contained within the case and is configured to receive and process the signal from each antenna so as to derive and output an indication of a characteristic of the target tissue.

US Pat. No. 10,136,832

REAL-TIME STIMULATION ARTIFACT SUPPRESSION FOR SIMULTANEOUS ELECTROPHYSIOLOGICAL ELECTRICAL STIMULATION AND RECORDING

THE REGENTS OF THE UNIVER...

1. An electrophysiological electrical stimulation and recording apparatus with stimulation artifact suppression, comprising:(a) a control circuit configured for controlling stimulus generation, artifact suppression and recording of a response to the generated stimulus;
(b) a current mode neural stimulator coupled to said control circuit, for amplifying an output from the control circuit to a recording/STI electrode;
(c) a first response amplification stage configured for amplifying the difference between a reference electrode and said recording/STI electrode as a measured stimulus response signal without amplifier saturation;
(d) a second response amplification stage configured for amplifying the difference between said measured stimulus response signal and a subtraction signal selected by said control circuit;
(e) wherein said control circuit is configured for:
(i) setting said subtraction signal to a fixed reference voltage;
(ii) generating a stimulus signal to said stimulus amplifier and storing an output from said second response amplification stage as a first artifact template;
(iii) calibrating the first artifact template by generating a stimulus signal to said stimulus amplifier while outputting said first artifact template as said subtraction signal to said second response amplification stage whose output is used to calibrate said first artifact template as a second artifact template; and
(iv) performing simultaneous stimulation and measurements by outputting said second artifact template as said subtraction signal to said second response amplification stage when outputting a stimulus signals to said stimulus amplifier connected to said recording/STI electrode;
(v) wherein subtraction of said second artifact template from the measured stimulus response signal results in removal of the artifacts from the measured stimulus response signal.

US Pat. No. 10,136,830

NEUROPHYSIOLOGICAL DATA ANALYSIS USING SPATIOTEMPORAL PARCELLATION

Elminda Ltd., Herzliya (...

1. A method of analyzing neurophysiological data recorded from a brain of a subject, the method comprising:recording the neurophysiological data by a plurality of measuring devices respectively placed at a plurality of different locations on the scalp of the subject,
operating a data processor for:
identifying activity-related features in the data;
parceling the data according to said activity-related features to define a plurality of capsules, each representing a spatiotemporal activity region in the brain and corresponding to an extremum of the data and a spatiotemporal neighborhood defined as a spatial region in which said extremum is located and a time-interval during which said extremum occurs, wherein a size of said neighborhood is determined based on a property of said extremum;
storing said capsules in a memory;
comparing at least some of said defined capsules to at least one reference capsule;
estimating a brain function of the subject based on said comparison and;
generating on a display an output indicative of said brain function.

US Pat. No. 10,136,829

SYSTEMS AND METHODS FOR USING ELECTROPHYSIOLOGY PROPERTIES FOR CLASSIFYING ARRHYTHMIA SOURCES

St. Jude Medical, Cardiol...

1. A method for determining electrophysiology properties of tissue, the method comprising:acquiring electrical signal data from a plurality of electrodes of one or more catheters;
determining at least one electrode clique from the plurality of adjacent electrodes, wherein the at least one electrode clique comprises at least three adjacent electrodes;
computing local conduction velocity vectors for the at least one electrode clique;
determining at least one catheter orientation independent indicator from which to classify an arrhythmia source based on one or more of an angular dependence parameter associated with a flow field of the local velocity conduction vectors, an eccentricity parameter reflecting the uniformity of local conduction velocity, and divergence and curl-like sums or closed path integral parameters associated with the local conduction velocity vectors; and
displaying a rhythm classification responsive to catheter movement thereby facilitating identification of types and causes of arrhythmia disorders.

US Pat. No. 10,136,827

HAND-HELD VITAL SIGNS MONITOR

SOTERA WIRELESS, INC., S...

1. A hand-held vital signs system, comprising:a housing comprising a microprocessor that is operably connected to a touch screen display on a surface of the housing to provide operation controls for the vital signs system on an icon-driven graphical user interface;
at least two electrodes operably connected to the microprocessor configured to measure an electrical signal which is processed by the microprocessor to provide an ECG waveform; and
a first sensor operably connected to the microprocessor configured to measure a low-frequency waveform comprising frequency components of between 40 Hz and 500 Hz indicative of heart valve operation;
a second sensor operably connected to the microprocessor configured to measure an optical waveform,
wherein the microprocessor is configured to collectively process the low-frequency waveform and the ECG waveform to determine a pre-ejection period, to collectively process the optical waveform, the ECG waveform and the pre-ejection period to determine a vascular transit time, and to determine a blood pressure value using the vascular transit time.

US Pat. No. 10,136,826

SYSTEM AND METHOD FOR DISTINGUISHING A CARDIAC EVENT FROM NOISE IN AN ELECTROCARDIOGRAM (ECG) SIGNAL

ZOLL MEDICAL CORPORATION,...

1. A wearable defibrillator comprising:at least one therapy pad for rendering treatment to a patient wearing the wearable defibrillator;
at least one sensing electrode for obtaining an electrocardiogram (ECG) signal from the patient;
a processing unit comprising at least one processor operatively coupled to the at least one therapy pad and the at least one sensing electrode; and
at least one non-transitory computer-readable medium comprising program instructions that, when executed by the at least one processor, causes the processing unit to:
obtain the ECG signal;
determine a transformed ECG signal based on the ECG signal;
extract at least one value representing at least one feature of the transformed ECG signal;
provide the at least one value to determine a score associated with the ECG signal, thereby providing an ECG-derived score;
compare the ECG-derived score to a predetermined threshold score determined by machine learning; and
provide an indication of a cardiac event based on the comparison of the ECG-derived score with the predetermined threshold score,
wherein the transformed ECG signal comprises a power spectral density (PSD) of the ECG signal, the PSD being determined by calculating a fast Fourier transform (FFT) of the ECG signal, and
wherein at least four features of the PSD are extracted and provided to the machine learning.

US Pat. No. 10,136,825

LONG-TERM IMPLANTABLE SILICON CARBIDE NEURAL INTERFACE DEVICE USING THE ELECTRICAL FIELD EFFECT

University of South Flori...

1. An implantable neural interface device, the device comprising:a control unit;
at least one substantially planar neural probe coupled to the control unit, each of the at least one substantially planar neural probes comprising;
at least one neural tissue stimulation device comprising at least one electrolyte insulator semiconductor capacitor (EISCap) having a cubic silicon carbide (3C—SiC) base and a biocompatible and chemically resistant gate insulator, wherein neural tissue in contact with the electrolyte insulator semiconductor capacitor (EISCap) forms a gate conductor to generate an electric field to stimulate the neural tissue at least partially surrounding the at least one substantially planar neural probe; and
at least one neural tissue stimulation receiving device comprising at least one field effect transistor having a cubic silicon carbide (3C—SiC) base, wherein neural tissue in contact with the at least one field effect transistor forms a gate conductor and wherein the at least one neural tissue stimulation receiving device receives ionic changes generated by the neural tissue resulting from the electric field stimulation by the at least one neural tissue stimulation device.

US Pat. No. 10,136,824

ARTERIAL SPIN LABELING (ASL) WITH MAGNETIC RESONANCE FINGERPRINTING (MRF)

Case Western Reserve Univ...

1. A method for performing arterial spin labeling (ASL) with magnetic resonance fingerprinting (MRF), comprising:selecting an ASL-MRF pulse sequence to apply to an object, where the ASL-MRF pulse sequence includes a labeling pulse and a control pulse;
controlling a magnetic resonance (MR) apparatus to apply the ASL-MRF pulse sequence to the object;
acquiring a nuclear magnetic resonance (NMR) signal evolution from the object, where the NMR signal evolution depends, at least in part, on a property of the arterial spins in the object;
selecting an entry in an MRF dictionary associated with the NMR signal evolution, and
simultaneously quantifying two or more properties of the arterial spins in the object based, at least in part, on the entry.

US Pat. No. 10,136,822

METHOD AND APPARATUS FOR NON-INVASIVELY DETECTING BLOOD VOLUME IMBALANCES IN A MAMMALIAN SUBJECT

Zynex Monitoring Solution...

1. An apparatus for noninvasively detecting blood volume changes in a mammalian subject, the apparatus comprising: a number of noninvasive sensors, communicable with the subject to obtain baseline and real time (current) physiologic value measurements from the subject; and at least one integrated circuit, operably connected with the sensors and configured to i) compute a real time (current) blood volume index from the physiologic value measurements wherein the blood volume index is derived from at least three physiological parameters selected from the group including heart rate, electrical body impedance, skin temperature, peripheral blood flow and skin humidity and wherein measurements of electrical body impedance, skin temperature, peripheral blood flow and skin humidity are taken at one or more extremities of the subject, and wherein the parameters are monitored by obtaining real time (current) value measurements for the parameters which are inputted into an algorithm which computes the real time (current) blood volume index based upon the differences between the baseline and real time (current) value measurements and wherein the algorithm includes coefficients for accurately weighting each parameter in the real time blood volume index, and wherein said algorithm for computing the real time (current) blood volume index=(100*(1?(((BINormalized?BIBaseline)/BIBaseline)*BICoefficient)?(((HRRealtime?HRBaseline)/HRBaseline*HRCoefficient)+(((PBFRealtime?PBFBaseline)/PBFBaseline*PBFCoefficient)?(((GSRRealtime?GSRBaseline)/GSRBaseline*GSRCoefficient)+(((STempRealtime?STempBaseline)/STempBaseline*STempCoefficient))) wherein BINormalized is peripheral bioimpedance normalized by removing known physiological drift, BICoefficient=0.725, HRCoefficient=0.145, PBFCoefficient=0.043, GSRCoefficient=0.014, and StempCoefficient=0.072, and ii) display the real time (current) blood volume index on a display of the apparatus, wherein the display is initially set to display a starting value blood volume index of 100 which indicates 100% of the subject's normal total blood volume, and wherein the displayed real time (current) blood volume index is capable of indicating a blood volume change in the subject as low as 10% of the subject's total blood volume.

US Pat. No. 10,136,821

IMAGE GENERATING APPARATUS, IMAGE GENERATING METHOD, AND PROGRAM

CANON KABUSHIKI KAISHA, ...

1. An apparatus for generating a photoacoustic image based on an acoustic wave caused by irradiation of light on an object, comprising:a determination unit configured to determine a propagation velocity of the acoustic wave; and
an image generation unit configured to generate the photoacoustic image based on the propagation velocity and a signal obtained by detecting the acoustic wave;
wherein the determination unit is configured to
set, based on an ultrasonic image obtained by transmitting and receiving an ultrasonic wave, a target position, and
determine, based on the signal corresponding to the target position, the propagation velocity.

US Pat. No. 10,136,820

METHOD TO VISUALIZE VERY EARLY STAGE NEOPLASM OR OTHER LESIONS

1. A treatment evaluation method comprisinganalyzing a liquid biopsy sample from a patient for the presence of at least one detectable biomarker of a lesion for which the patient has a family history of predisposition before there is any clinical manifestation or radiographic evidence of the lesion,
generating one or more anti-tumor antibodies based upon the at least one biomarker of the lesion detected in the liquid biopsy sample,
conjugating the one or more anti-tumor antibodies with nanoparticles to form functionalized antibody-coated nanoparticles,
administering, to the patient, the functionalized antibody-coated nanoparticles having a detectable property, the nanoparticles being further coated with a thermosensitive polymer coating,
heating the nanoparticles with an energy source to generate photoacoustic signals,
performing photoacoustic imaging with a photoacoustic imager to visualize any locally accumulated nanoparticles at a body site in the patient,
imaging the lesion at the site so as to determine the location of the lesion in or on the body of the patient by means of the locally accumulated nanoparticles, the lesion being otherwise radiographically undetectable absent the locally accumulated nanoparticles,
where the heating of the nanoparticles with the energy source further comprises heating the nanoparticles from a body temperature of 37° C. to a temperature between 40° C. and 43° C. to melt the thermosensitive polymer coating and release at least one of a medication, a gene together with a CRISPR/cas9 complex, or a checkpoint inhibitor from the nanoparticles,
treating the patient for the lesion by the release of the at least one medication, gene together with the CRISPR/cas9 complex, or checkpoint inhibitor from the nanoparticles locally at the location of the lesion, and
performing the method at least one time post-treatment to evaluate the treatment outcome quantifying the presence or absence of circulating cells or exosomes in the patient.

US Pat. No. 10,136,819

SHORT-WAVE INFRARED SUPER-CONTINUUM LASERS AND SIMILAR LIGHT SOURCES FOR IMAGING APPLICATIONS

Omni Medsci, Inc., Ann A...

1. An imaging device, comprising:a first part of the imaging device comprising a first at least one of a plurality of laser diodes, the first at least one of the plurality of laser diodes configured to be pulsed;
a second part of the imaging device comprising a second at least one of the plurality of laser diodes;
the plurality of laser diodes configured to generate light having one or more optical wavelengths, wherein at least a portion of the one or more optical wavelengths is a near-infrared wavelength between 700 nanometers and 2500 nanometers;
a first one or more lenses configured to receive at least a portion of the light from the plurality of laser diodes and to direct at least the portion of the light to tissue;
an array of laser diodes configured to generate light formed as a plurality of spots, the light having one or more optical wavelengths, wherein at least a portion of the one or more optical wavelengths is a near-infrared wavelength between 700 nanometers and 2500 nanometers;
a second one or more lenses configured to receive at least a portion of the light from the array of laser diodes and to direct at least the portion of the light from the array of laser diodes to tissue;
a first receiver comprising one or more detectors;
the first receiver configured to receive at least a portion of light reflected from the tissue from the first one of the plurality of laser diodes, wherein the first receiver is configured to be synchronized to the at least one of the plurality of pulsed laser diodes and is configured to perform a time-of-flight measurement;
an infrared camera configured to receive at least a portion of light from the second one of the plurality of laser diodes reflected from the tissue;
the infrared camera configured to:
generate a first signal while the plurality of laser diodes and the array of laser diodes are off; and
generate a second signal while the second part of the imaging device is on and the first part of the imaging device and the array of laser diodes are off, the second signal based at least in part on a portion of the light from the second part of the imaging device reflected from the tissue;
wherein the infrared camera is configured to difference the first signal and the second signal to generate a two-dimensional or three-dimensional image;
the imaging device coupled to one of a smart phone, tablet, or computer, the smart phone, tablet, or computer comprising a wireless receiver, a wireless transmitter, a display, a voice input module, and a speaker, the smart phone, tablet, or computer configured to receive and to process at least a portion of the time-of-flight measurement, the two-dimensional or three-dimensional image, and the received light from the plurality of spots reflected from the tissue.

US Pat. No. 10,136,818

HIGH RESOLUTION INTRAOPERATIVE MRI IMAGES

Tel Hashomer Medical Rese...

1. A method of providing an intraoperative magnetic resonance image of a target site of a patient body at which a medical procedure is performed, the method comprising:acquiring a high resolution preoperative magnetic resonance image (MRI), MRIo, of a first region of the patient comprising the target site, the MRIo image comprising a plurality of slices MRIo,n having voxels;
acquiring a preoperative, iMRIo image of a second region of the patient comprising the target site, using an iMRI scanner having a field of view (FOV), the iMRIo image comprising a plurality of slices iMRIo,m having voxels;
registering the MRIo image to the iMRIo image to provide a rigid body transform (iRT0) that transforms image MRIo to image iMRIo;
acquiring an iMRI1 image of the target site during performance of the medical procedure;
registering image iMRIo to image iMRI1 to determine a non-rigid body transform (NRT1); and
applying iRT0 and NRT1 to image MRIo to provide a high resolution (hiQ-iMRI1) image.

US Pat. No. 10,136,816

MEDICAL DEVICES AND METHODS

Abbott Diabetes Care Inc....

1. A system, comprising:an analyte sensor configured to be in fluid contact with bodily fluid under a skin surface;
sensor electronics including a memory, the sensor electronics operatively coupled to the analyte sensor to receive signals generated by the analyte sensor and to log data in the memory corresponding to the received signals generated by the analyte sensor, and further configured to detect a transmitted query; and
a display device configured for data communication with the sensor electronics, the display device comprising:
a storage device having stored therein one or more routines;
a processing unit operatively coupled to the storage device and configured to retrieve the stored one or more routines for execution;
a data transmission component operatively coupled to the processing unit and configured to transmit data based at least in part on the one or more routines executed by the processing unit; and
a data reception component operatively coupled to the processing unit and configured to receive analyte related data from the sensor electronics and to store the received analyte related data in the storage device;
wherein the data transmission component is programmed to transmit a query to the sensor electronics;
wherein the data reception component receives the analyte related data from the sensor electronics in response to the transmitted query when the sensor electronics transitions from a low power state to a fully operational state in response to detection of the query from the data transmission component by the sensor electronics; and
wherein the sensor electronics is configured to overwrite the logged data in the memory prior to an expiration of a life of the analyte sensor with new data corresponding to signals obtained from the analyte sensor after the expiration of the analyte sensor life, the sensor electronics configured to communicate to the data reception component of the display device the analyte related data that includes the logged data in the memory including the new data corresponding to the signals obtained from the analyte sensor after the expiration of the analyte sensor life.

US Pat. No. 10,136,814

AUTOMATIC PATHWAY AND WAYPOINT GENERATION AND NAVIGATION METHOD

COVIDIEN LP, Mansfield, ...

1. A method of providing a pathway from a starting point to a target location within a patient, comprising:selecting a target location within a patient;
using a processor to execute instructions stored on a non-transitory computer-readable storage medium to cause the processor to determine a pathway from a starting point to the target location by beginning at the target location and following back to the starting point, wherein determining the pathway includes assigning at least one waypoint along the pathway;
positioning a locatable guide at the starting point; and
advancing the locatable guide from the starting point to the target location following the determined pathway,
wherein determining the pathway further includes:
calculating an airway diameter along a path, as a candidate for the pathway, from the target to the starting point;
detecting a decrease in the airway diameter along the path; and
aborting the path if the decrease in the airway diameter is detected.

US Pat. No. 10,136,813

SYSTEMS AND METHODS FOR PATIENT CARDIOVASCULAR AND RESPIRATORY MANAGEMENT

1. A method for displaying integrated graphics for diagnostics for a patient's physiology, the method comprising:displaying a cardiac graphic object representing cardiac performance based on at least one measurement from the patient's left ventricle performance, said cardiac graphic object including at least a first, second, and third physiological parameter;
displaying at least one dynamic graphical line from the first physiological parameter being displayed to the second physiological parameter being displayed, and wherein the displaying of the dynamic graphical line comprises illustrating at least one functional relationship between the first and second physiological parameters;
displaying a pulmonary graphic object representing pulmonary performance, wherein displaying the pulmonary graphic object comprises displaying pulmonary vascular blood flow, and wherein the displaying the pulmonary vascular blood flow comprises displaying at least one measurement based on the patient's pulmonary arterial blood pressure and at least one measurement based on the patient's pulmonary venous blood pressure, and at least one measurement based on the patient's pulmonary vascular resistance; and
displaying a systemic vascular graphic object representing systemic cardiovascular performance, wherein displaying the systemic vascular graphic object comprises displaying systemic vascular blood flow, wherein the displaying the systemic vascular blood flow comprises displaying at least one measurement based on the patient's systemic arterial blood pressure and at least one measurement based on the patient's systemic venous blood pressure, and at least one measurement based on the patient's systemic vascular resistance.

US Pat. No. 10,136,810

SYSTEMS AND METHODS FOR DIAGNOSIS AND THERAPY OF VISION STABILITY DYSFUNCTION

NEUROSCIENCE RESEARCH AUS...

1. A device for obtaining vestibulo-ocular reflex data from a patient having a head and at least one eye, the device including:a frame configured for mounting to the patient;
a target module mounted to the frame and being responsive to a drive signal to project a selectively movable target object onto a surface in front of the patient;
an eye tracking module mounted to the frame, the module being adapted for obtaining first data indicative of one or more characteristics of the at least one eye; and
a head tracking module mounted to the frame, the head tracking module being adapted for obtaining second data indicative of one or more characteristics of the motion of the head.

US Pat. No. 10,136,809

OPHTHALMIC APPARATUS

KABUSHIKI KAISHA TOPCON, ...

1. An ophthalmic apparatus comprising:a refractive power measurement unit configured to project light from a light source onto a subject's eye and detect returning light thereof to determine refractive power of an ocular optical system of the subject's eye; and
an eyeball information measurement unit configured to project light from the light source onto the subject's eye and detect returning light thereof to determine eyeball information representing structure of the subject's eye.

US Pat. No. 10,136,808

OPTICAL COHERENCE TOMOGRAPHY AS A RAPID, ACCURATE, NON-CONTACT METHOD OF VISUALIZING THE PALISADES OF VOGT

1. A method of imaging palisades of Vogt comprising:imaging the palisades of Vogt via a non-contact in-vivo or ex-vivo process to acquire an image, wherein the imaging the palisades of Vogt via a non-contact in-vivo process to acquire the image comprises acquiring high-resolution images rapidly at a predetermined distance from a patient by directing laser light at a corneal limbus of the patient and measuring a delay caused by reflection of the laser light from the corneal limbus, wherein recognition of tissue boundaries depends on contrast between backscattered and/or reflected signal strength;
transferring the image to an analyzing component;
identifying in the analyzing component structures represented in the image to determine a status of the image;
and
storing the image in a data storage component for future evaluation or comparison.

US Pat. No. 10,136,806

IMAGE DISPLAY METHOD, IMAGE DISPLAY APPARATUS, AND STORAGE MEDIUM

Canon Kabushiki Kaisha, ...

1. An image display method comprising:acquiring a first image of a fundus within a first area of an eye to be inspected;
acquiring interference signal sets corresponding to a plurality of frames, which are acquired with an intention to acquire the same cross section, for a plurality of different cross sections;
generating, based on the interference signal sets corresponding to the plurality of frames, a motion contrast image of the fundus within a second area included in the first area; and
superimposing, for display, information acquired from a portion of the motion contrast image of the fundus onto a corresponding position of the first image of the fundus.

US Pat. No. 10,136,805

APPARATUS, SYSTEM, AND METHOD FOR INTRAOCULAR LENS POWER CALCULATION USING A REGRESSION FORMULA INCORPORATING CORNEAL SPHERICAL ABERRATION

AMO Groningen B.V., Gron...

1. A system for predicting optical power for an intraocular lens, comprising:a first device configured to measure at least one biometric parameter of an eye;
a second device configured to obtain a corneal spherical aberration of the eye according to the at least one biometric parameter;
at least one computing processor configured to apply a modified regression to the at least one biometric parameter and the corneal spherical aberration to output a prediction of an optical power for an intraocular lens to obtain a desired postoperative condition, wherein the modified regression is of the form:
optical power=Regression+constant0*(corneal spherical aberration)
or
optical power=constant1*(biometric parameter)+constant0*(corneal spherical aberration);
wherein constant1 and constant0 comprise an empirically derived factor across other eyes, and wherein Regression comprises a classical regression.

US Pat. No. 10,136,803

RING ILLUMINATED SURGICAL CAMERA

InnovaQuartz LLC, Phoeni...

1. A ring illuminated surgical camera comprising:a ring lens that includes
an emission surface adjacent to a distal end,
a reflector,
an external surface,
a proximal void adjacent to a proximal end, and
an electric wire conduit port passing through the emissions surface and adapted to carry an electronic imaging sensor and imaging sensor electrical contacts; and
a plurality of light emitting diodes (LEDs) carried within the proximal void, adjacent to an internal surface of the ring lens, and adapted to radially emit light.

US Pat. No. 10,136,802

DEVICE FOR SUSTAINED RELEASE OF OPTICAL CLEARING AGENT, ENDOSCOPE HAVING THE SAME, AND INSTRUMENT FOR ENDOSCOPIC SURGERY HAVING THE SAME

OLYMPUS CORPORATION, Tok...

1. A method for achieving sustained release of optical clearing agent comprising:(a) inserting into a lumen a device for sustained release of optical clearing agent without inflating any of at least two pouch-shaped elastic components of the device, the device comprising:
a stick-shaped component inside which at least two supplying passages are formed for supplying gas or liquid and which has apertures of the respective supplying passages formed at positions in a vicinity of a top end of the stick-shaped component along a circumference of a lateral surface thereof,
the at least two pouch-shaped elastic components placed at positions in the vicinity of the top end of the stick-shaped component along the circumference of the lateral surface of the stick-shaped component to cover the respective apertures of the supplying passages respectively;
(b) moving the device for sustained release of optical clearing agent so that the top end of the stick-shaped component, where the pouch-shaped elastic components are provided, is positioned to a diseased region on a wall surface of the lumen;
(c) rotating the stick-shaped component via a rotary unit until a body-fluid absorbing component fixed on a surface of a first pouch-shaped elastic component, which is one of the at least two pouch-shaped elastic components, is made to face the diseased region;
(d) infusing gas or liquid into the first pouch-shaped elastic component from the aperture of a first supplying passage, which is one of the at least two supplying passages inside the stick-shaped component, via the first supplying passage, to inflate the first pouch-shaped elastic component;
(e) pressing the body-fluid absorbing component against the diseased region through deformation of the first pouch-shaped elastic component, to make the body-fluid absorbing component absorb body fluid on a surface of and from inside the diseased region;
(f) discharging the gas or fluid from inside the first pouch-shaped elastic component through the aperture of the first supplying passage, to deflate the first pouch-shaped elastic component and detach the body-fluid absorbing component from the diseased region;
(g) rotating the stick-shaped component via the rotary unit until an optical clearing agent holding component fixed on a surface of a second pouch-shaped elastic component, which is one of the at least two pouch-shaped elastic components, is made to face the diseased region;
(h) infusing gas or liquid into the second pouch-shaped elastic component from the aperture of a second supplying passage, which is one of the at least two supplying passages inside the stick-shaped component, via the second supplying passage, to inflate the second pouch-shaped elastic component; and
(i) pressing the optical clearing agent holding component against the diseased region through deformation of the second pouch-shaped elastic component, to establish sustained release of optical clearing agent held by the optical clearing agent holding component to the diseased region.

US Pat. No. 10,136,801

BENDING PORTION AND ENDOSCOPE

OLYMPUS CORPORATION, Tok...

1. A bending portion in which a plurality of bending pieces are pivotably continuously provided, the bending portion comprising:a first bending piece and a second bending piece provided adjacent to each other;
the first bending piece comprising:
a circular convex portion comprising a peripheral portion having a circular arc shape;
a support portion extended along an axial line direction of the first bending piece from a circular convex portion and supporting the circular convex portion;
a pair of engaging concave portions provided so as to sandwich the circular convex portion and the support portion; and
a pair of distal-end-side contact portions respectively extended from the engaging concave portions in an opposite direction of the circular convex portion,
the pair of engaging concave portions each comprising:
a first inclined portion extended from the support portion in a direction to form an obtuse angle with the support portion;
a second inclined portion extended from the first inclined portion in a direction to form an obtuse angle with the first inclined portion; and
an inside portion that is bent in an obtuse angle with respect to the second inclined portion and extended along a concentric arc of the peripheral portion so as to be adjacent to the distal-end-side contact portion; and
the second bending piece comprising:
a circular concave portion comprising an inside portion having a circular arc shape configured to slide with respect to the peripheral portion, the circular concave portion being provided so as to be pivotable around the circular convex portion;
a pair of engaging convex portions provided so as to sandwich the circular concave portion; and
a pair of proximal-end-side contact portions respectively extended from the engaging convex portions in an opposite direction from the circular concave portion, the pair of proximal-end-side contact portions being configured to come into contact with the distal-end-side contact portions when the circular concave portion pivots around the circular convex portion,
the pair of engaging convex portions each comprising:
 a pair of pointed portions having a shape along the support portion, the first inclined portion, and the second inclined portion, one of the pair of pointed portions being placed at a back of the engaging concave portion to face the support portion, the first inclined portion, and the second inclined portion when the distal-end-side contact portions and the proximal-end-side contact portion contact with each other; and
 an outside portion that is bent in an obtuse angle with respect to the pointed portions and extended along a concentric arc of the inside portion so as to be adjacent to the proximal-end-side contact portion.

US Pat. No. 10,136,800

BENDING OPERATION DEVICE AND ENDOSCOPE

OLYMPUS CORPORATION, Tok...

1. A bending operation device, comprising:a bending lever that is inclinably supported with respect to an operation section of an endoscope;
an arm part that is provided on the bending lever and includes a distal end displaceable in conjunction with inclination operation of the bending lever; and
an intermediate lever, wherein
the intermediate lever includes a fixed end and a free end that are set on both ends in a longitudinal direction of the intermediate lever, the fixed end being swingably supported with respect to the operation section via a fulcrum, the intermediate lever further includes a force point between the fixed end and the free end and a point of application at a position on the intermediate lever that is farther from the fulcrum than the force point and is closer to the free end than the force point, the force point being connected to the distal end of the arm part through an intermediate wire, the point of application being connected to a bending wire, and the bending wire bending a bending portion provided in an insertion section of the endoscope.

US Pat. No. 10,136,798

ENDOSCOPIC SYSTEM

OLYMPUS CORPORATION, Tok...

1. An endoscopic system comprising:an endoscope comprising:
an insertion portion configured to be inserted into a body, the insertion portion having a channel to insert a treatment instrument through the channel, and
an operation portion connected to the insertion portion, the operation portion including a grasping portion configured to be grasped by a surgeon and an operation lever rotatably provided in the operation portion, the operation lever including a catching portion that catches the treatment instrument, the operation lever being configured to move the treatment instrument while being held by the catching portion to transmit a force of operation by the surgeon to the treatment instrument; and
an assistant instrument which assists the movement of the treatment instrument, the assistant instrument comprising:
a flexible tube in which an insertion path is formed to insert the treatment instrument,
a coupling portion which connects one end of the flexible tube and the channel so that the channel communicates with the insertion path, and
a holding portion including a base body connected to an other end of the flexible tube, the holding portion further including an attachment instrument attached to the operation portion so that the base body is disposed on a side of the operation portion where the operation lever is disposed.

US Pat. No. 10,136,797

ENDOSCOPE WITH EXTERNAL DEVICE CONNECTOR

FUJIFILM Corporation, To...

1. An endoscope apparatus, comprisingan insertion part that is inserted into a body cavity of a subject;
an operating part that is connected to the insertion part;
a universal cord that extends from the operating part; and
a connector part that is provided at a terminal of the universal cord away from the insertion part and is connected to an external device and transmits and receives a light signal to and from the external device,
wherein the connector part comprises:
a hollow metal member having two openings that communicate with each other;
an optical semiconductor element that is fixed to one opening side of the hollow metal member so as to be capable of sealing the periphery of the one opening;
a lens that is provided on the other opening side of the hollow metal member; and
a first sealing member that fixes the lens to the hollow metal member and seals a gap between the lens and the hollow metal member.

US Pat. No. 10,136,796

MEDICAL DEVICE POSITIONING SYSTEM

Boston Scientific Scimed,...

1. A medical device, comprising:an insertion portion, including:
a proximal portion including a first engagement member, the first engagement member including one of:
(a) a helical groove that leads into a linear groove, and
(b) a pin,
wherein the proximal portion further includes a deflectable endoscope shaft,
a distal portion rotatably coupled to the proximal portion, the distal portion including:
a laterally-facing opening, and
a second engagement member, the second engagement member including the other of the helical groove and the pin, the pin being slidably received by the helical groove and by the linear groove, wherein:
the helical groove extends at least 360 degrees about at least one of the proximal portion and the distal portion,
a longitudinal axis of the linear groove extends parallel to a longitudinal axis of the insertion portion,
engagement between the helical groove and the pin allows rotation of the distal portion relative to the proximal portion through an angle up to at least 360 degrees, and
rotation of the distal portion is caused by sliding of the pin along and against the helical groove as the distal portion is forced in one of a proximal direction and a distal direction.

US Pat. No. 10,136,795

DISH RACK RETAINING CLIP

Whirlpool Corporation, B...

1. A dish rack assembly, comprising:a dish rack having spaced wire frame elements at least partially defining a dish rack side wall and configured to retain dishes;
a height adjuster comprising an arm located on an exterior of the dish rack side wall having a pair of spaced first ribs extending therefrom with each of the pair of spaced first ribs extending along a different wire frame element, the height adjust further including a lever and wherein the arm is configured to be operably coupled to a tub side wall and the lever is configured to move the arm vertically to adjust the height of the dish rack with respect to the tub side wall; and
a retaining clip located on an interior of the dish rack side wall and having a planar body with a pair of second ribs extending therefrom, each of the pair of second ribs is complementary to each of the pair of first ribs;
wherein the retaining clip is mounted to the arm such that a first of the pair of first ribs and a first of the pair of second ribs are directly adjacent opposite lateral sides of a first of the spaced wire frame elements and the arm and retaining clip are on opposite sides, transverse to the lateral sides, of the first of the spaced wire frame elements and a second of the pair of first ribs and a second of the pair of second ribs are directly adjacent opposite lateral sides of a second of the spaced wire frame elements and the arm and retaining clip are on opposite sides, transverse to the lateral sides, of the second of the spaced wire frame elements.

US Pat. No. 10,136,794

MOVABLE CUTLERY BASKET

BSH Home Appliances Corpo...

1. A dishwasher rack, comprising:a frame including at least two contiguous sides disposed along a perimeter of the rack, the two sides including a first side and a second side;
a support rail disposed along the at least two sides of the frame such that the rail includes a first portion corresponding to the first side of the frame and a second portion corresponding to the second side of the frame; and
at least one cutlery basket coupled to the rail and arranged to be movable along the perimeter of the rack from the first portion of the rail to the second portion of the rail without disengaging from the rail as the at least one cutlery basket moves from the first portion of the rail to the second portion of the rail or vise versa.

US Pat. No. 10,136,793

DISHWASHER

Whirlpool Corporation, B...

1. A dishwasher comprising:a tub having an open face and at least partially defining a treating chamber receiving dishes for treatment and having a tub air outlet located in an upper portion of the tub and a tub air inlet located in a lower portion of the tub;
a door assembly moveable between an opened position and a closed position where the door assembly closes the open face;
an airflow conduit extending along a portion of the tub and fluidly coupling the tub air outlet to ambient air;
a blower assembly forcing air to flow from the tub and through the tub air outlet into the airflow conduit;
a first reservoir associated with the airflow conduit and located vertically between the tub air outlet and tub air inlet, the first reservoir collecting liquid condensed from the air forced through the airflow conduit, the first reservoir having a liquid outlet at a nadir of the first reservoir and wherein the liquid outlet is fluidly coupled to an opening the tub via a liquid conduit for draining the collected liquid into the tub and wherein the opening in the tub comprises a water inlet for the tub, wherein the water inlet receives water from a household water supply; and
a second reservoir associated with the airflow conduit downstream of the first reservoir and collecting liquid condensed from the air prior to exhaustion of the air to the ambient air;
wherein any liquid not collected by the first reservoir is collected by the second reservoir for evaporation.

US Pat. No. 10,136,792

HOUSEHOLD APPLIANCE

1. A household appliance assembly, comprising:a household appliance having a treatment container which defines a treatment chamber;
at least one packing element including a positioning aid and disposed on a side face of the household appliance, wherein the packing element is adapted to prevent damage to the household appliance due to forces occurring during at least one of storage and transportation of the household appliance, and the positioning aid includes one of a projection and a recess; and
the household appliance further comprising at least one load-bearing structural part with a cross-sectional profile that includes the other of the projection and the recess, the at least one load-bearing structural part being positioned externally of the treatment chamber, such that the other of the projection and the recess of the at least one load-bearing structural part is exposed so as to be accessible from outside of the household appliance,
wherein the packing element has at least one force transfer region, which has a force action surface in direct contact with the load-bearing structural part,
the household appliance is configured to be a built-in appliance that does not have external casing walls at least where the packing element is disposed, and
the cross-sectional profile is inserted into the positioning aid or the positioning aid is inserted into the cross-sectional profile such that the projection and the recess are in contour-matched contact.

US Pat. No. 10,136,790

APPLICATOR FOR SANITIZING AND/OR DISINFECTING SOLUTION

TIETEX INTERNATIONAL, LTD...

1. A textile applicator of fibrous construction for application of a liquid sanitizing or disinfecting solution to a surface, the applicator comprising:a plurality of multi-filament microfiber stitching yarns disposed in stitched relation through at least one layer of polyester or polypropylene fleece in a stitch-bonded fabric construction forming a liquid carrier fabric for collection and dispersal of the sanitizing or disinfecting solution, wherein the microfiber yarns comprise a plurality of direct spun polyester filaments characterized by a substantially circular cross sectional perimeter and a linear density of less than 1 denier per filament, the liquid carrier fabric being nonreactive with both quaternary ammonium compounds, and chlorine such that the concentration of quaternary ammonium compounds or chlorine in the sanitizing or disinfecting solution degrades by not more than about 10% following immersion of the liquid carrier fabric in the sanitizing or disinfecting solution for a period of one hour.

US Pat. No. 10,136,789

ALL-IN-ONE SQUEEZABLE SCRUBBING TOOL

The Clorox Company, Oakl...

1. A cleaning device comprising:(a) a squeezable container housing comprising a bottom wall and a fluid reservoir and an outlet for dispensing, wherein the fluid reservoir is configured such that a lateral depth of the fluid reservoir is at a maximum between upper and lower ends of the reservoir, and the lateral depth of the fluid reservoir gradually decreases from the maximum to the upper end of the fluid reservoir, and the lateral depth of the fluid reservoir gradually decreases from the maximum to the lower end of the fluid reservoir;
(b) a volume of a cleaning composition disposed within the fluid reservoir, wherein the cleaning composition comprises a hypochlorite;
(c) a dispensing valve disposed at or near the outlet, and in fluid communication with the reservoir, the dispensing valve being configured to dispense a cleaning composition from the reservoir through the dispensing valve when the cleaning composition is present in the reservoir and a user squeezes the container housing which subsequently opens the dispensing valve in response to a pressure increase in the reservoir;
(d) a sled having a generally planar configuration and located downstream of the dispensing valve; and
(e) a substrate attached to the sled, the substrate being disposed over or about a dispensing orifice of the dispensing valve so that upon squeezing the squeezable container housing, the cleaning composition, when present in the reservoir, is dispensed from the reservoir, through the dispensing orifice.

US Pat. No. 10,136,788

BROOM

1. A broom comprising a head and a handle, wherein the head comprises:a first portion having a plurality of bristles on a first side surface thereof;
a second portion extending outwardly from a first longitudinal side of the first portion at an angle thereto;
a recess in a distal edge of the second portion extending from adjacent a first end of the second portion to adjacent a second end of the second portion;
a scraper blade comprising an elongate member fixed at least partially within the recess such that at least portions of longitudinal ends of the scraper blade are enclosed by sections of the second portion located between the ends of the recess and longitudinal ends of the second portion;
wherein the outer edge of the scraper blade extends beyond the second portion of the head in order to contact the ground for scraping.

US Pat. No. 10,136,787

IMAGE PROCESSING METHOD AND IMAGE PROCESSING APPARATUS WHICH CAN PERFORM BACKGROUND NOISE REMOVING BASED ON COMBINED IMAGE

PixArt Imaging Inc., Hsi...

1. An image processing method, applied to an image processing apparatus comprising a light source and an image sensor, wherein the image sensing method comprises:acquiring a first image via the image sensor when the light source does not emit light;
acquiring a second image via the image sensor when the light source emits light;
acquiring a third image via the image sensor when the light source operates does not emit light;
generating a combined image based on only part of contents of the first image and only part of contents of the third image, but not based on the second image; and
acquiring a target image after background noise removing via subtracting the combined image from second image.

US Pat. No. 10,136,786

CHARGING STAND FOR VACUUM CLEANER

JIANGSU MIDEA CLEANING AP...

1. A charging stand for a vacuum cleaner, comprising:a body having a battery charger; and
a blade vertically disposed on the body, wherein the blade extends curvedly along a length direction of the blade and is configured to cut off hairs wound around a brushroll of the vacuum cleaner.

US Pat. No. 10,136,785

VACUUM CLEANER HAVING A FILTER CLEANING MECHANISM

SHOP VAC CORPORATION, Wi...

1. A vacuum cleaner having a filter cleaning mechanism, comprising:a housing having an exterior side and an interior side, and a channel extending through the housing from the exterior side to the interior side;
a vacuum pump to draw air into the interior side of the housing;
a vacuum filter disposed on the interior side of the housing to filter the air;
a filter brush contacting a side of the vacuum filter;
a rod extending slidably through the channel and coupled to the filter brush; and
a handle coupled to the rod, wherein movement of the handle slides the rod through the channel and moves the filter brush along the side of the vacuum filter to remove debris from the filter, wherein the handle rotates from a folded position against the exterior side of the housing to an upright position; and
wherein the handle comprises a cam to translate rotation of the handle into linear movement of the handle.

US Pat. No. 10,136,782

MULTI-FUNCTION COMBINED BRUSH FOR VACUUM CLEANER

Spival S.P.A., Larciano ...

1. A combined brush for vacuum cleaner comprising at least one suction duct, one fixed part, and two or several frames, each movable with respect to said fixed part from a retracted position to an extracted position, wherein each of said two or several movable frames is extracted or retracted according to an alternating translatory movement controlled by the intermittent rotation of a shaft, wherein the extraction of each movable frame takes place at at least one angular position of said shaft, said at least one angular position being different from the angular positions at which the other or the other movable frames are extracted.

US Pat. No. 10,136,781

FLOOR CLEANER, AND CLEANING MECHANISM FOR CLEARING CLEANING ROLLER

HiZero Technologies Co., ...

1. A cleaning mechanism for clearing a cleaning roller of a cleaner, the cleaning mechanism comprising:a cleaning roller for cleaning ground;
a clearing component operating to clear the cleaning roller;
a scraper having an arc-shaped surface facing the cleaning roller, wherein the scraper defines an opening in which the clearing component is disposed; and
a power unit, wherein:
the clearing component comprises a rotation body and a plurality of clearing elements disposed on the rotation body for clearing a surface of the cleaning roller,
the power unit operates to drive the rotation body and each of the plurality of clearing elements to rotate along with the cleaning roller in a same direction,
a top surface of the scraper and a base shell, spaced apart from the scraper, define the opening, and
the scraper is disposed between the cleaning roller and a trash bin.
US Pat. No. 10,137,201

PROCESS FOR FORMULATING AN ANIONIC AGENT

DICERNA PHARMACEUTICALS, ...

1. A method of producing a particle comprising an anionic agent the method comprising:(a) combining in an acidic aqueous solution (i) a modified lipid which prevents particle aggregation during lipid-anionic agent particle formation and (ii) a cationic lipid, in an amount sufficient for a complex to form;
(b) combining the complex of step (a) with an anionic agent;
(c) combining a neutral aqueous solution with the complex-anionic agent of step (b) to form a complex-anionic agent aqueous suspension;
(d) forming a solution or suspension comprising an alcohol and at least one lipid selected from the group consisting of a neutral lipid, a sterol, a cationic lipid and a modified lipid which prevents particle aggregation during lipid-anionic agent particle formation; and
(e) adding the solution or suspension of step (d) to the complex-anionic agent aqueous suspension of step (c), thereby causing the concentration of the alcohol in the complex-anionic agent aqueous suspension to gradually increase from 0% to up to no more than 40% (v/v) as more of the solution of step (d) is added to the complex-anionic agent aqueous solution of step (c), thereby producing a particle comprising an anionic agent.
US Pat. No. 10,137,202

ANTIBODY-DRUG CONJUGATES AND IMMUNOTOXINS

Oncomatryx Biopharma, S.L...

1. A conjugate having the formula I:A-(L-D)p  (I)
or a pharmaceutically acceptable salt or solvate thereof,
wherein:
A is an antibody that selectively binds fibroblast activation protein alpha (FAP), said antibody comprising heavy chain complementarity determining regions 1-3 (CDRH1-3) and light chain complementarity determining regions 1-3 (CDRL1-3) having the following amino acid sequences:
(i) CDRH1: SEQ ID NO: 7;
(ii) CDRH2: SEQ ID NO: 8;
(iii) CDRH3: SEQ ID NO: 9;
(iv) CDRL1: SEQ ID NO: 10;
(v) CDRL2: SEQ ID NO: 11; and
(vi) CDRL3: SEQ ID NO: 12;
L is a linker;
D is a drug comprising a cytolysin; and
p is 1 to 10.
US Pat. No. 10,137,203

HER2 APTAMER-ANTICANCER DRUG COMPLEX FOR CANCER CELL CHEMOTHERAPY

Korea University Research...

1. A method of manufacturing a complex for cancer cell chemotherapy, comprising:a) preparing a nucleic acid aptamer consisting of the base sequence of SEQ ID NO:1 for specifically binding to HER2; and
b) forming an aptamer-anticancer drug complex by reacting the aptamer with anticancer drug DM1;
wherein the aptamer includes a thiol group introduced at the 3? terminal end and DM1 includes a thiol group such that a disulfide bond is formed between the aptamer and DM1.
US Pat. No. 10,138,485

NEUTRAL NANOTRANSPORTERS

RXi Pharmaceuticals Corpo...

1. A composition comprising:a hydrophobic modified polynucleotide, wherein the hydrophobic modified polynucleotide comprises an isolated double stranded nucleic acid molecule comprising a guide strand and a passenger strand, wherein the isolated double stranded nucleic acid molecule includes a double stranded region and a single stranded region, wherein the double stranded region is from 8-14 nucleotides long, wherein the single stranded region is at the 3? end of the guide strand and is 4-12 nucleotides long, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the isolated double stranded nucleic acid molecule are modified, and wherein a hydrophobic conjugate is attached to the isolated double stranded nucleic acid molecule at the 3? end of the sense strand, and wherein the isolated double stranded nucleic acid molecule does not form a hairpin;
a neutral fatty mixture comprising at least 20% dioleoylphosphatidylcholine (DOPC) or distearoylphosphatidylcholine (DSPC), and at least 20% sterol; and
optionally a cargo molecule,
wherein the hydrophobic modified polynucleotide and the neutral fatty mixture forms a micelle.
US Pat. No. 10,137,205

THYMIDYLATE KINASE FUSIONS AND USES THEREOF

University Health Network...

1. A composition comprising:(a) a stably integrating delivery vector;
(b) a polynucleotide encoding a modified human thymidylate kinase (tmpk), wherein the modified human tmpk increases phosphorylation of 3?-azido-3?-deoxythymidine (AZT) relative to phosphorylation of AZT by wild-type human tmpk; and
(c) a polynucleotide encoding a detection cassette polypeptide that is expressed on the surface of a cell, wherein the polynucleotide encoding the detection cassette polypeptide is fused to the polynucleotide encoding the modified human tmpk and the detection cassette polypeptide is fused to the modified human tmpk;
wherein the modified human tmpk comprises a modification selected from the group consisting of (i) a F to Y mutation at amino acid position 105 of SEQ ID NO: 11; (ii) a R to G mutation at amino acid position 16 of SEQ ID NO: 12; and (iii) a R to A mutation at amino acid position 200 of SEQ ID NO: 16.
US Pat. No. 10,138,486

INHIBITORS OF DEK PROTEIN AND RELATED METHODS

THE REGENTS OF THE UNIVER...

1. A method of treating or ameliorating an inflammatory condition in a patient, comprising administering to said patient a therapeutically effective amount of a single-stranded anti-DEK DNA aptamer, and a pharmaceutically acceptable carrier, wherein said anti-DEK DNA aptamer is SEQ ID NO:1, SEQ ID NO: 2 or SEQ ID NO:6.
US Pat. No. 10,137,206

NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF

FACTOR BIOSCIENCE INC., ...

1. A method for treating a subject, comprising administering a synthetic RNA encoding a gene-editing protein targeting an immune checkpoint molecule gene, wherein the gene-editing protein comprises:(a) a DNA-binding domain comprising a plurality of repeat sequences and at least one of the repeat sequences comprises the amino acid sequence: LTPvQWAlAwxyzGHGG (SEQ ID NO: 629) and is between 36 and 39 amino acids long, wherein:
“v” is Q, D or E,
“w” is S or N,
“x” is H, N, or I,
“y” is D, A, I, N, G, H, K, S, or null, and
“z” is GGKQALETVQRLLPVLCQD (SEQ ID NO: 630) or GGKQALETVQRLLPVLCQA (SEQ ID NO: 631); and
(b) a nuclease domain comprising a catalytic domain of a nuclease.
US Pat. No. 10,137,208

VIVO TUMOR TARGETING AND SPECTROSCOPIC DETECTION WITH SURFACE-ENHANCED RAMAN NANOPARTICLE TAGS

Emory University, Atlant...

1. A surface-enhanced Raman spectroscopic active composite nanostructure comprising:a single-core metallic nanoparticle with a diameter of 100 nm or less;
a Raman reporter molecule disposed on the surface of the core; and
an encapsulating protective layer disposed on the surface of the core and the reporter molecule, wherein the encapsulating protective layer is a thiolpolyethylene glycol, and wherein the encapsulated reporter molecule has a measurable surface-enhanced Raman spectroscopic signature.
US Pat. No. 10,138,489

CYANOBACTERIAL STRAINS CAPABLE OF UTILIZING PHOSPHITE

Algenol Biotech LLC, For...

1. A genetically modified cyanobacterial cell for the production of a product of interest, comprising:a) at least one recombinant gene that encodes a heterologous phosphite dehydrogenase enzyme EC:1.20.1.1 that catalyzes the oxidation of phosphite to phosphate, wherein said enzyme has at least 85% identity to the protein sequence of the Ralstonia phosphite dehydrogenase enzyme (SEQ ID NO: 12);
b) an operon comprising at least one recombinant phosphite transporter gene encoding at least one phosphite transporter protein for transporting phosphite into the cell wherein the at least one phosphite transporter protein has at least 85% identity to a protein sequence selected from the group consisting of Cyanothece PtxA (SEQ ID NO: 19), Cyanothece PtxB (SEQ ID NO:22), Cyanothece PtxC (SEQ ID NO: 25), and Desulfotignum phosphitoxidans PtdC (SEQ ID NO: 28);
c) a knockout or knockdown of a gene encoding an endogenous protein having at least 85% identity to the repressor protein PhoU; and
d) at least one recombinant production gene encoding a polypeptide for the production of said product of interest.
US Pat. No. 10,138,490

TRANSFORMED PLANTS TOLERANT TO HERBICIDES DUE TO OVEREXPRESSION OF PREPHENATE DEHYDROGENASE AND P-HYDROXYPHENYLPYRUVATE DIOXYGENASE

1. A method for cultivating a transformed plant, the method comprisinga) planting a seed of the transformed plant,
b) contacting the seed or a transformed plant grown from the seed with a herbicidal composition comprising an inhibitor of p-hydroxyphenylpyruvate dioxygenase, and
c) cultivating the plant, wherein the transformed seed or the transformed plant is substantially unaffected by the herbicidal composition, wherein the plant comprises:
(1) a first gene that is functional in a plant, wherein the first gene comprises a nucleotide sequence that encodes a yeast prephenate dehydrogenase, and
(2) a second gene that is functional in a plant, wherein the second gene comprises a nucleotide sequence that encodes a p-hydroxyphenylpyruvate dioxygenase, and
wherein the plant overexpresses the prephenate dehydrogenase and the p-hydroxyphenylpyruvate dioxygenase, and wherein said plant is tolerant to an amount of said inhibitor that is toxic to or decreases the growth of plants transformed with said second gene alone.
US Pat. No. 10,138,234

2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-A]PYRIDINE DERIVATIVES

Hoffmann-La Roche Inc., ...

1. A compound selected from the group consisting of:N-(2-fluoroethyl)-2-phenylimidazo[1,2-a]pyridin-7-amine,
N-(2-fluoroethyl)-N-methyl-2-phenylimidazo[1,2-a]pyridin-7-amine,
N,N-dimethyl-2-phenylimidazo[1,2-a]pyridin-7-amine,
N-methyl-2-phenylimidazo[1,2-a]pyridin-7-amine,
[2-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
(2-[4-(2-fluoro-ethoxy)-phenyl]-imidazo[1,2-a]pyridin-7-yl}-dimethyl-amine,
[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
N-methyl-2-m-tolylimidazo[1,2-a]pyridin-7-amine,
N,N-dimethyl-(2-m-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
N,N-dimethyl-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
N-methyl-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
N-(2-fluoroethyl)-N-methyl-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
2-(4-(dimethylamino)phenyl)-N-(2-fluoroethyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
[2-(3-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
(2-fluoro-ethyl)-methyl-(2-m-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine
[2-(3-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyri din-7-yl]-methyl-amine,
(2-fluoro-ethyl)-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
(2-fluoro-ethyl)-(2-m-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
(2-fluoro-ethyl)-[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
[2-(3,4-dimethyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
[2-(3,4-dimethyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
[3H]-[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
[3H]—N-methyl-2-phenyl-imidazo[1,2-a]pyridin-7-amine,
[3H]—N-(2-fluoroethyl)-2-phenyl-imidazo[1,2-a]pyridin-7-amine,
[3H]—N-methyl-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
(2-fluoro-ethyl)-[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
[2-(3,4-dimethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
cyclopropyl-[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
methyl-[2-(4-methyl sulfanyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
[2-(3,4-dimethyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-(2-fluoro-ethyl)-amine,
[2-(3,4-dimethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-(2-fluoro-ethyl)-amine,
[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
(2-fluoro-ethyl)-[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
(2-fluoro-ethyl)-[2-(3-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
[2-(3-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
(2-fluoro-ethyl)-[2-(4-methyl sulfanyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
cyclopropyl-[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
2-methoxy-4-(7-methylamino-imidazo[1,2-a]pyridin-2-yl)-phenol,
3-(7-dimethylamino-imidazo[1,2-a]pyridin-2-yl)-phenol,
[4-[7-(methylamino)imidazo[1,2-a]pyridin-2-yl]phenyl]methanol,
[4-[7-(dimethylamino)imidazo[1,2-a]pyridin-2-yl]phenyl]methanol,
2-(3,5-dimethoxyphenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
N-[2-(4-ethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
methyl-[2-(4-pyrrolidin-1-yl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
N-[2-(3-fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
N-[2-(4-diethylamino-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
N-[2-(4-ethyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
2-[4-(methoxymethyl)phenyl]-N,N-dimethyl-imidazo[1,2-a]pyridin-7-amine,
methyl-[2-(4-morpholin-4-yl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
2-[4-(2-fluoroethoxymethyl)phenyl]-N,N-dimethyl-imidazo[1,2-a]pyridin-7-amine,
2-(3-methoxy-4-methylphenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
2-[4-(2-fluoroethoxy)phenyl]-N-methylimidazo[1,2-a]pyridin-7-amine,
2-(4-(benzyl(methyl)amino)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
N-[2-(4-difluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
N-[2-(4-bromo-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
methyl-[2-(4-piperidin-1-yl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
2-(7-methylamino-imidazo[1,2-a]pyridin-2-yl)-phenol,
methyl 3-[7-(methylamino)imidazo[1,2-a]pyridin-2-yl]benzoate,
[3-[7-(methylamino)imidazo[1,2-a]pyridin-2-yl]phenyl]methanol,
N-cyclopropyl-2-[4-(2-fluoroethoxy)phenyl]imidazo[1,2-a]pyridin-7-amine,
7-(azetidin-1-yl)-2-[4-(3-fluoropropoxy)phenyl]imidazo[1,2-a]pyridine,
4-methyl-2-(7-methylamino-imidazo[1,2-a]pyridin-2-yl)-phenol,
2-[3-(methoxymethyl)phenyl]-N-methyl-imidazo[1,2-a]pyridine-7-amine,
2-(4-(2-fluoroethylamino)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
N-(3-fluoropropyl)-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-7-amine,
2-(3-(fluoromethoxy)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
2-(2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-7-ylamino)propan-1-ol,
N-(2-fluoroethyl)-2-(3-methoxy-4-methylphenyl)imidazo[1,2-a]pyridin-7-amine,
N-methyl-2-(3-(methylthio)phenyl)imidazo[1,2-a]pyridin-7-amine,
2-(3-(2-fluoroethoxy)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
2-(3-(3-fluoropropoxy)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
2-(4-(4-fluoropiperidin-1-yl)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
4-(7-(2-fluoroethylamino)imidazo[1,2-a]pyridin-2-yl)-2-methoxyphenol,
4-(7-(2-fluoroethylamino)imidazo[1,2-a]pyridin-2-yl)phenol,
3-(7-(2-fluoroethylamino)imidazo[1,2-a]pyridin-2-yl)phenol,
N-(2-fluoroethyl)-2-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyridin-7-amine, and
N-cyclopropyl-2-[4-(3-fluoropropoxy)phenyl]imidazo[1,2-a]pyridin-7-amine, or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,138,491

PROTEIN HAVING GLYCOALKALOID BIOSYNTHETIC ENZYME ACTIVITY AND GENE ENCODING THE SAME

KIRIN HOLDINGS KABUSHIKI ...

1. A transformed solanaceous plant having reduced glycoalkaloid content in which the expression of a gene encoding a protein having glycoalkaloid biosynthetic enzyme activity is suppressed, wherein the suppression of the gene is induced by RNAi, and wherein the gene comprises a DNA selected from the group consisting of (a) to (c);(a) DNA consisting of the nucleotide sequence shown in SEQ ID NO: 2, 4, 19 or 21;
(b) DNA that consists of a nucleotide sequence having 90% or more sequence identity to the nucleotide sequence shown in SEQ ID NO: 2, 4, 19 or 21; and
(c) DNA consisting of a degenerate isomer of the nucleotide sequence shown in SEQ ID NO: 2, 4, 19 or 21.
US Pat. No. 10,139,003

LIP SEAL FOR WATER PUMP

Eagle Industry Co., Ltd.,...

1. A lip seal for water pump made of a rubber-like elastic material, fixed to a housing as a fixed side and in sliding contact with a shaft rotating relative to the housing;the lip seal having sliding surface with a surface roughness Ra (according to JIS B0601 corresponding to ISO 4287) of 1 to 30 ?m, being obtained by vulcanization-molding of a rubber composition comprising 100 parts by weight of hydrogenated nitrile rubber or EPDM, 1 to 150 parts by weight of a reinforcing filler, 5 to 90 parts by weight of a non-reinforcing filler having an average particle diameter of 1 ?m or more, 0.1 to 5 parts by weight of a coupling agent, 1 to 15 parts by weight of a co-crosslinking agent, and 0.5 to 10 parts by weight of an organic peroxide.
US Pat. No. 10,138,492

NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING IMPROVED NITROGEN USE EFFICIENCY CHARACTERISTICS IN PLANTS

Ceres, Inc., Thousand Oa...

1. A method of producing a plant, said method comprising(a) growing a plant cell comprising an exogenous nucleic acid, said exogenous nucleic acid comprising a regulatory region operably linked to a nucleotide sequence, said nucleotide sequence comprising 95 percent or greater sequence identity to the nucleotide sequence of SEQ ID NO:48, or wherein said nucleotide sequence encodes a polypeptide comprising 95 percent or greater sequence identity to the amino acid sequence of SEQ ID NO:49;
(b) growing a plant from said plant cell; and
(c) selecting for a plant comprising an increased level of low-nitrogen tolerance as compared to the corresponding level of low-nitrogen tolerance of a control plant that does not comprise said nucleic acid.
US Pat. No. 10,138,493

SYNTHETIC TRANSCRIPTIONAL AND EPIGENETIC REGULATORS BASED ON ENGINEERED, ORTHOGONAL ZINC FINGER PROTEINS

TRUSTEES OF BOSTON UNIVER...

1. An engineered responsive promoter comprising (a) at least one target DNA sequence element selected from the group consisting of 5?-CGTCGAAGTCGAAGTCGACC-3? (SEQ ID NO: 81), 5?-GGACGACGTTACGGACGTAC-3? (SEQ ID NO: 82), 5?-A GACGTCGAAGTAGCCGTAG-3? (SEQ ID NO: 83), 5?-GGACGACGCCGATGTAGAAG-3? (SEQ ID NO: 84), 5?-TGAAGCAGTCGACGCCGAAG-3? (SEQ ID NO: 85), 5?-GGACGACGCGGTCTAAGAAG-3? (SEQ ID NO: 86), 5?-CGACGAGGTCGCATAAGTAG-3? (SEQ ID NO: 87), 5?-AGACGCAGTATAGGTCGAAC-3? (SEQ ID NO: 88), 5?-AGACGCAGTATAGGACGACG-3? (SEQ ID NO: 89), 5?-CGGCGTAGCCGATGTCGCGC-3? (SEQ ID NO: 90), and 5?-GGTCGTTGCGGTAGTCGAAG-3? (SEQ ID NO: 91) and (b) a promoter sequence, wherein the at least one target DNA sequence element is operably linked at the 5? end of the promoter sequence in order to influence transcription initiation of a nearby coding sequence.
US Pat. No. 10,136,957

LEAK RESISTANT ARTICLE

Ansell Limited, Victoria...

1. A leak-resistant elastomeric barrier comprising:an elastomeric barrier comprising elastomeric polymer, having two sides, and coated on at least a portion of a first side with highly hydrophobic coating such that the initial contact angle with water at 23±2° C. is about 130° or more, and that contact angle does not decay by more than about 10% over 40 minutes.
US Pat. No. 10,138,495

BIO-PRODUCTION OF LENTIVIRAL VECTORS

Calimmune, Inc., Tucson,...

1. A recombinant plasmid comprising a nucleotide sequence having at least 90% identity to the sequence of SEQ ID NO: 1.
US Pat. No. 10,137,215

ORGANIC WASTE ODOR ABSORBER

1. A method of treating organic waste comprising:a step of placing a composition within a receptacle to create a layer on the bottom of said receptacle;
a step of placing organic waste within said receptacle already containing the layer of said composition, where said organic waste is placed on top of said composition;
a step of placing additional said composition on top of said organic waste within said receptacle;wherein said composition's materials comprise:a. 35% to 85% holocellulose, by weight
b. 8% to 30% lignin, by weight
c. 40% to 80% silica, by weight;wherein said composition comprises dried materials;wherein said composition's materials comprise a particle size range from 0.002 millimeters in diameter to 300 by 300 by 300 millimeters;wherein said composition comprises a scent;wherein said organic waste is composted.
US Pat. No. 10,138,239

PREPARATION METHOD OF CRYSTALLINE FORM A OF PCI-32765

Crystal Pharmatech Co. LT...

1. A preparation method of PCI-32765 crystalline Form A wherein the preparation method comprises the following steps:1) preparing a PCI-32765 free base solution by dissolving the free base solid of PCI-32765 in a solvent;
2) adding dropwise the solution prepared by step 1) into an anti-solvent at a temperature of 0-20° C., then stirring the mixture at a temperature of 0-20° C. and adding seed crystals of PCI-32765 Form A to form a suspension; or adding dropwise the solution prepared by step 1) into a suspension containing seed crystals of PCI-32765 Form A at a temperature of 0-20° C. to form a suspensions;
3) continuously stirring the suspension obtained by step 2) and aging the suspension until a crystal slurry is obtained;
4) filtering the crystal in step 3) to obtain a filter cake, then washing and drying the filter cake to obtain a powder of PCI-32765 crystalline Form A.
US Pat. No. 10,138,496

VECTORS WITH MODIFIED INITIATION CODON FOR THE TRANSLATION OF AAV-REP78 USEFUL FOR PRODUCTION OF AAV

uniQure IP B.V., Amsterd...

1. A method of producing a recombinant parvoviral viron in an insect cell comprising, transfecting and insect cell with a nucleotide sequence encoding parvoviral Rep proteins Rep78 and Rep52, the nucleotide sequence comprising a Rep78 coding sequence and a Rep52 coding sequence, the Rep78 coding sequence and the Rep52 coding sequence being operably linked to expression control sequences for expression of both a Rep78 protein and a Rep52 protein in an insect cell; wherein the Rep52 coding sequence is comprised within the Rep78 coding sequence, and wherein a molar ratio of Rep78 and Rep52 in the range of 1:10 to 10:1 is produced when the nucleotide sequence is expressed in the insect cell.
US Pat. No. 10,138,498

RECOMBINANT MICROORGANISMS FOR ENHANCED PRODUCTION OF MEVALONATE, ISOPRENE, AND ISOPRENOIDS

Danisco US Inc., Palo Al...

1. Recombinant bacterial or yeast cells capable of increased production of isoprenoids, wherein the cells are engineered by(i) modulation of citrate synthase activity such that the activity of citrate synthase is Decreased;
(ii) modulation of the activities of one or more of the following enzymes such that:
(a) phosphotransacetylase activity is attenuated;
(b) acetate kinase activity is attenuated; and/or
(c) lactate dehydrogenase activity is attenuated; and
(iii) modulation of the activity of two or more of the following enzymes such that (d) malate dehydrogenase activity is increased, (e) pyruvate dehydrogenase activity is increased, and/or (f) phosphoenolpyruvate carboxylase activity is attenuated, resulting in increased carbon flux towards mevalonate production;
wherein the cells further comprise (A) one or more nucleic acids encoding one or more mevalonate (MVA) pathway polypeptides; and (B) one or more nucleic acids encoding a polyprenyl pyrophosphate synthase; and
wherein the cells produce increased amounts of isoprenoids compared to isoprenoid-producing cells that do not comprise (i-iii).
US Pat. No. 10,137,218

DISINFECTION SYSTEM OF CONTACT LENS

MENICON CO., LTD., Nagoy...

1. A method for disinfecting a contact lens comprising:contacting a contact lens with a contact lens disinfecting solution having a pH of from 6 to 8 and including 1 to 10% hydrogen peroxide and 0.1% to 5% by weight of at least one of an organic carboxylic acid and a salt thereof, wherein the organic carboxylic acid includes a structure in which a hydroxyl group and a carboxyl group are bonded to one carbon atom, and
neutralizing the hydrogen peroxide in the disinfecting solution by contacting the disinfecting solution with a metal catalyst for a treatment duration in which the level of hydrogen peroxide in the disinfecting solution is reduced to a concentration of 200 ppm or less, the treatment duration being a shorter time period than a period that would otherwise be required to neutralize hydrogen peroxide to the same concentration with the metal catalyst in a like contact lens disinfecting solution without the organic carboxylic acid.
US Pat. No. 10,138,499

METHODS FOR IMPROVING THE EFFICIENCY OF SIMULTANEOUS SACCHARIFICATION AND FERMENTATION REACTIONS

DANISCO US INC., Palo Al...

1. A method for simultaneous saccharification and fermentation (SSF) comprising culturing a complete fermentation medium, said complete fermentation medium comprising at least one fermenting microorganism, at least one xylan-containing biomass, at least one cellulase, at least one hemicellulase, at least one retaining ?-xylosidase, and at least one inverting ?-xylosidase, for a period and under conditions suitable for producing a fermentation product, which is an alcohol, wherein the at least one inverting ?-xylosidase comprises an Fv43D polypeptide having at least 90% sequence identity to SEQ ID NO:2, or to residues 21 to 350 of SEQ ID NO:2, and the complete fermentation medium comprises a greater amount of the at least one inverting ?-xylosidase than that of the at least one retaining ?-xylosidase on a mole basis.
US Pat. No. 10,137,475

COATING SYSTEM, A METHOD OF APPLYING THE COATING SYSTEM AND AN ARTICLE COMPRISING THE COATING SYSTEM

Dow Global Technologies L...

1. A method of applying a multi-layer coating system comprising:(I) selecting an epoxy formulation which comprises
(a1) epoxy resin;
(a2) curing agent selected from the group consisting of amine adducts, amides, polyamides, and Mannich bases derived from polyfunctional amines with no more than 4.5 wt % free amine based on a weight solids of the curing agent; and
(II) applying the epoxy formulation onto a substrate;
(III) fully or partially curing the epoxy formulation to produce an epoxy coating layer;
(IV) selecting a non-isocyanate polyurethane formulation;
(V) applying the non-isocyanate polyurethane formulation onto the epoxy coating layer; and
(VI) allowing the topcoat formulation and epoxy formulation to fully cure thereby forming a multi-layer coating system;
wherein the epoxy formulation and/or non-isocyanate polyurethane formulation optionally further comprise one or more additives selected from the group consisting of solvent, reactive diluent, plasticizer, pigment, filler; rheology modifiers, dispersants, surfactants, UV stabilizers, and corrosion inhibitors.
US Pat. No. 10,138,500

D-LACTIC ACID-PRODUCING STRAIN AND USE THEREOF

CJ CHEIJEDANG CORPORATION...

1. A D-lactic acid-producing strain modified to attenuate or inactivate L-lactate dehydrogenase (L-LDH) activity and to enhance D-lactate dehydrogenase (D-LDH) activity, wherein the D-lactic acid-producing strain so modified is a Lactobacillus sp strain which produces more L-lactic acid than D-lactic acid prior to said modification; wherein the L-LDH activity is derived from a L-LDH-encoding polynucleotide from Lactobacillus paracasei, Lactobacillus casei, or Lactobacillus rhamnosus; wherein the D-LDH activity is derived from a D-LDH-encoding polynucleotide from Lactobacillus plantarum or Lactobacillus delbrueckii; and wherein the Lactobacillus sp. strain is selected from the group consisting of Lactobacillus casei, Lactobacillus paracasei, and Lactobacillus rhamnosus.
US Pat. No. 10,136,708

LIGHT PRECIOUS ALLOY OF GOLD AND TITANIUM AND COMPONENTS FOR TIMEPIECES OR JEWELLERY MADE FROM SUCH A LIGHT PRECIOUS ALLOY OF GOLD AND TITANIUM

1. A light, precious gold-titanium based alloy comprising, by mass, from 750‰ to 780‰ of gold,wherein said alloy has the following composition formula:
TiaAubMcTd
where a b, c, d are atomic proportions such that:
a+b+c+d=1,
0.45?a?0.55; 0.41?b?0.495; 0.025?c?0.13; 0.001?d?0.025,
wherein M represents at least one element selected from the group consisting of Nb, V, Pd, Pt, and Fe, and
T represents boron and optionally an additional element, and
wherein the additional element is selected from the group consisting of Nb, V, Pd, Pt, Fe, Mo, Ta, W, Co, Ni, Ru, Rh, Ir, Cr, Mn, Cu, Zn, Ag, Al, Si, Ge, Sn, Sb, and In,
M and T are different elements, and
the alloy comprises the boron as T or as a part of T in an atomic content of from 0.03% to 0.3%.
US Pat. No. 10,137,476

COATING AGENT FOR CORROSION-RESISTANT COATINGS

1. A multicoat color and/or effect paint system comprising, lying above one another in this order,(1) at least one first basecoat comprising a basecoat material (A);
(2) a second color and/or effect basecoat comprising a basecoat material (B); and
(3) at least one transparent coating comprising a clearcoat material (C);
wherein the basecoat material (A) comprises:
(a.1) at least one binder,
(a.2) at least one color or effect pigment, and
(a.3) at least one water-soluble or water-dispersible, corrosion-inhibiting, oligomeric or polymeric component comprising:
a parent structure (GK) comprising at least two repeating monomer units (ME) and
at least one uni- and/or multidentate, potentially anionic ligand (L) capable of forming complexes after the multicoat paint system has been thermally cured,
wherein the monomer units (ME) are ethylenimines units and the ligand (L) is hydroxyacetophenone.
US Pat. No. 10,138,501

METHOD FOR PREPARING DIGLYCERIDE USING BUBBLE COLUMN REACTOR

Jinan University, Guangz...

1. A method for synthesizing diglyceride using a bubble column reactor, characterized by comprising the steps of:(1) placing an immobilized enzyme on the bearing mechanism of the bubble column reactor, and a hot bath mechanism is actuated to heat the reactor body to 55-75° C.;
(2) adding glycerol and fatty acid in a feed chute as reactants, and water is added as an activating enzyme catalyst; wherein the molar ratio of glycerol and fatty acid is 1:1-10:1; the added amount of water is less than 10% of the total mass of the reactants; and the added amount of the immobilized enzyme in step (1) is 1-10% of the total mass of the reactants;
(3) preheating glycerin, fatty acids and water in the feed chute to 55-75° C., then charged into the reactor body to initiate a synthesis reaction; a blowing mechanism is actuated and the flow rate of an inert gas is controlled at 0.7-5.7 cm/s, so that the inert gas is continuously blown into the reactor body via a sieve plate, forming boiling bubbles;
(4) turning off the hot bath mechanism and the blowing mechanism after the synthesis reaction is carried out for 15-90 min, stopping the heating and the inert gas circulation, actuating a compacting mechanism, and standing and layering the reaction mixture, thus obtaining an upper layer, which is a crude glycerin layer, and a lower layer, which is a glycerol layer; the crude glycerin layer is removed off the free fatty acids via a first-stage molecular distillation, then sent into a second-stage molecular distillation, thus obtaining a distillate and a distillation residue; wherein the distillate is high purity diglyceride, and the distillation residue is monoglyceride;
wherein the bubble column reactor in step (1) comprises a reactor body, a bearing mechanism, a sieve plate, a compacting mechanism, a blowing mechanism, a hot bath mechanism, a feed chute, and a connecting cylinder, wherein the reactor body, the bearing mechanism and the connecting cylinder are connected sequentially from top to bottom; the hot bath mechanism, the reactor body, and feed chute are sequentially connected, and formed a hot bath circulation; the reactor body is communicated with the connecting cylinder, the connecting cylinder is connected to the blowing mechanism, the sieve plate is placed on the upper end of the connecting cylinder, the compacting mechanism is mounted on the connecting cylinder, the upper end of the compacting mechanism is inserted into the connecting cylinder, and the upper end of the compacting mechanism is abutted against the sieve plate;
wherein the compacting mechanism comprises a floating joint, a cylinder, a compacting head, wherein the piston rod of the cylinder is connected to the compacting head via the floating joint, the compacting head is abutted against the sieve plate; the upper end of the compacting head is provided with a first upper cavity, the first upper cavity is communicated with the internal cavity of the reactor body via the sieve plate, the bottom surface of the first upper cavity is arranged in an inclined mode; the lower end of the compacting head is provided with a first lower cavity, the floating joint is connected to the first lower cavity; the side wall of the upper end of the compacting head is provided with a first through hole, the first through hole is communicated with the first upper cavity and the internal cavity of the connecting cylinder; and
wherein the internal cavity of the connecting cylinder is provided with flow-guiding plate, the internal cavity of the connecting cylinder is divided into a second upper cavity and the second upper cavity by the flow-guiding plate, the second upper cavity is communicated with the internal cavity of the reactor body, the flow-guiding plate is arranged in an inclined mode, the middle of the flow-guiding plate is provided with a second through hole through which the piston rod of the cylinder passes, the floating joint is sleeved with a sealing sleeve, the sealing sleeve is closely connected to the second through hole; the connecting cylinder is provided with a gas ventilating hole and a liquid collecting hole, both the gas ventilating hole and the liquid collecting hole are communicated with the second upper cavity, the gas ventilating hole is connected to the blowing mechanism; the axis of the liquid collecting hole is arranged in parallel with the flow-guiding plate, and the lower end of the flow-guiding plate is at the same height as that of the lower edge of the liquid collecting hole.
US Pat. No. 10,137,733

PNEUMATIC TIRE

SUMITOMO RUBBER INDUSTRIE...

1. A pneumatic tire, comprising a tread formed from a rubber composition,the rubber composition comprising:
an oil-extended polybutadiene rubber having a cis content of 95 mol % or more, a vinyl content of 1 mol % or less, and a weight average molecular weight of 530,000 or more;
at least one of an isoprene-based diene rubber or a styrene-butadiene rubber;
a carbon black having a nitrogen adsorption specific surface area of 110 to 200 m2/g; and
stearic acid,
the oil-extended polybutadiene rubber being synthesized using a rare earth catalyst,
the rubber composition comprising, based on 100% by mass of the total rubber solids, 8% to 65% by mass of a polybutadiene rubber component contained in the oil-extended polybutadiene rubber and 20% to 85% by mass of the at least one of an isoprene-based diene rubber or a styrene-butadiene rubber,
the rubber composition comprising, relative to 100 parts by mass of the total rubber solids, 20 to 100 parts by mass of the carbon black and 1.5 to 2.99 parts by mass of the stearic acid,
the rubber composition having an amount of process oil of 9 parts by mass or less relative to 100 parts by mass of the total rubber solids.
US Pat. No. 10,138,502

METHOD FOR PRODUCING OIL CONTAINING POLYUNSATURATED FATTY ACID USING LIPASE

NIPPON SUISAN KAISHA, LTD...

1. A method for lowering saturated fatty acid content in a glyceride containing a polyunsaturated fatty acid, the method comprising:concentrating the polyunsaturated fatty acid using a lipase having low reactivity for the polyunsaturated fatty acid to hydrolyze the glyceride containing the polyunsaturated fatty acid, wherein the glyceride containing the polyunsaturated fatty acid is a marine animal oil glyceride or a microorganism oil glyceride;
wherein the polyunsaturated fatty acid is a fatty acid having at least 20 carbon atoms and having at least 3 double bonds,
wherein the hydrolysis by the lipase is performed in the presence of 10 to 200 weight percent of water based on a total weight of the glyceride containing the polyunsaturated fatty acid, and at a temperature from 10° C. to 20° C.,
wherein the lipase is derived from a microorganism selected from the group consisting of Candida cylindracea and Alcaligenes sp.; and
wherein the saturated fatty acid content in the resulting glyceride is less than the saturated fatty acid content in the glyceride prior to the concentrating.
US Pat. No. 10,137,222

FIBRIN COMPOSITION, METHOD AND WOUND ARTICLES

3M INNOVATIVE PROPERTIES ...

1. A method of forming a fibrin hydrogel composition comprisingforming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt; wherein the fibrin hydrogel forming salt has a concentration greater than or equal to the threshold concentration to form a fibrin hydrogel;
reducing the salt concentration below the threshold concentration to form a fibrin hydrogel.
US Pat. No. 10,138,504

PRODUCTION OF MALONYL-COA DERIVED PRODUCTS VIA ANAEROBIC PATHWAYS

Lallemand Hungary Liquidi...

1. A recombinant yeast microorganism comprisingone or more engineered metabolic pathways to convert a carbohydrate source to a malonyl-CoA derived product,
wherein the one or more engineered metabolic pathways comprises
(a) the conversion of phosphoenolpyruvate to oxaloacetate by a phosphoenolpyruvate carboxykinase and
(b) the conversion of oxaloacetate and acetyl-CoA to malonyl-CoA and pyruvate by a heterologous transcarboxylase Enzyme Commission Number 2.1.3.1;
wherein the one or more engineered metabolic pathways further comprises downregulation or deletion of native pyruvate decarboxylase, and wherein the one or more engineered metabolic pathway further comprises heterologous pyruvate formate lyase.
US Pat. No. 10,137,224

ALLOGENEIC MICROVASCULAR TISSUE FOR SOFT TISSUE TREATMENTS

MICROVASCULAR TISSUES, IN...

1. A processed microvascular tissue comprising:a dried microvascular tissue, wherein the microvascular tissue comprises dissociated, and uncultured stem or progenitor cells having intact cell membranes, wherein the viability of the uncultured stem or progenitor cells in the processed microvascular tissue is less than 30%, and wherein the processed microvascular tissue has tissue healing activity.
US Pat. No. 10,138,505

PROCESS FOR THE PRODUCTION OF ORGANIC COMPOUNDS FROM PLANT SPECIES

Novamont S.p.A., Novara ...

1. A process for the production of fermentable C5-C6 sugars from oleaginous herbaceous plants belonging to the Cardueae tribe, comprising the steps of:a) mechanically separating the seeds from the above-ground lignocellulose biomass of the oleaginous herbaceous plants and comminuting said lignocellulose biomass;
b) bringing the comminuted lignocellulose biomass into contact with a basic aqueous solution containing 5 vol. % or less of an organic solvent in order to prepare an aqueous paste containing the comminuted lignocellulose biomass in an amount of 10 to 50% by weight, at a temperature of between 10 and 95° C. and for a time of between 1 minute and 24 hours;
c) separating the paste into a first solid fraction and a first liquid fraction;
d) subjecting the solid fraction to enzyme hydrolysis of the hemicellulose and cellulose contained therein.
US Pat. No. 10,137,225

CRYSTALLINE COATING AND RELEASE OF BIOACTIVE AGENTS

Yissum Research Developme...

1. A process of depositing at least a first layer of a first therapeutically active agent onto at least a continuous portion of a surface of an object, wherein at least 50 weight percents of said first layer is said first therapeutically active agent in a crystalline form, the process comprising:seeding said surface of said object with crystals of said first therapeutically active agent, so as to obtain a seeded surface comprising said crystals; and
contacting said seeded surface with a solution containing said first therapeutically active agent for at least 5 minutes, so as to effect precipitation of said first therapeutically active agent onto said seeded surface in a crystalline form, thereby forming said crystalline form of said first therapeutically active agent deposited on at least said portion of said surface,
wherein said surface is not cooled to a temperature below a temperature of said solution.
US Pat. No. 10,138,506

ENZYMATIC PRODUCTION OF D-TAGATOSE

BONUMOSE LLC, Charlottes...

1. An enzymatic process for preparing tagatose from a starch derivative, the process comprising the steps of:(i) converting a saccharide to glucose 1-phosphate (G1P) using alpha glucan phosphorylase (?GP), wherein the saccharide is selected from one or more derivatives of starch;
(ii) converting G1P to glucose 6-phosphate (G6P) using a phosphoglucomutase (PGM);
(iii) converting G6P to fructose 6-phosphate (F6P) using a phosphoglucoisomerase (PGI);
(iv) converting fructose 6-phosphate (F6P) to tagatose 6-phosphate (T6P) catalyzed by a fructose 6-phosphate epimerase (F6PE); and
(v) converting the T6P produced to tagatose catalyzed by a tagatose 6-phosphate phosphatase (T6PP)
wherein steps (i)-(v) are conducted in a single reaction vessel.
US Pat. No. 10,138,507

MANUFACTURING METHODS FOR PRODUCTION OF RNA TRANSCRIPTS

ModernaTX, Inc., Cambrid...

1. A method for producing a purified composition comprising a capped RNA transcript for a gene of interest, the method comprising:(a) providing a sample comprising a linear, non-amplified DNA template, the DNA template comprising an RNA polymerase promoter sequence operatively linked to a target sequence coding for the gene of interest, a poly A tail sequence of 60-160 nucleotides, an endonuclease recognition site sequence immediately downstream of the poly A tail sequence, and a 5? untranslated region (UTR) and/or a 3? UTR;
(b) contacting the sample with a RNA polymerase and ribonucleotides under conditions sufficient for vitro transcription to produce a first composition comprising an uncapped RNA transcript wherein at least 80% of the RNA transcript is full-length uncapped RNA transcript;
(c) purifying the uncapped RNA transcript using oligo dT affinity purification;
(d) capping the uncapped RNA transcript by contacting the RNA transcript with quanlyltransferase, s-adenosyl-L-methionine, guanosine triphosphate, and 2?-O-methyltransferase to produce a second composition comprising a capped RNA transcript;
(e) purifying the capped RNA transcript from the second composition by anion exchange chromatography; and
(f) filtering the capped RNA transcript by ultrafiltration or tangential flow filtration, thereby producing the purified composition comprising a capped RNA transcript,wherein the method does not comprise treating the composition with DNase.
US Pat. No. 10,138,509

METHOD FOR GENERATING A THREE-DIMENSIONAL NUCLEIC ACID CONTAINING MATRIX

President and Fellows of ...

1. A method of identifying nucleic acids within a cell, comprising:contacting a plurality of nucleic acids having a relative three-dimensional spatial relationship within the cell with a matrix-forming material in a manner to substantially retain the relative three-dimensional spatial relationship;
using the matrix-forming material to form a three-dimensional polymerized matrix including the nucleic acids of the plurality of nucleic acids covalently bound to the three-dimensional polymerized matrix; and
detecting signals from the nucleic acids or derivatives thereof, thereby identifying the nucleic acids.
US Pat. No. 10,138,510

DUAL LABELING METHODS FOR MEASURING CELLULAR PROLIFERATION

LIFE TECHNOLOGIES CORPORA...

1. A method for measuring a change in cellular DNA synthesis:a) incubating a sample with an effective amount of a first nucleoside or nucleotide analog comprising an ethynyl group to form a primary incubated sample,
wherein the first nucleoside or nucleotide analog is ethynyl-deoxyuracil (EdU);
b) incubating the primary incubated sample with a second nucleoside or nucleotide analog comprising a halogen moiety to form a secondary incubated sample,
wherein the second nucleoside or nucleotide analog is BrdU, and wherein the first nucleoside or nucleotide analog is not incorporated into a DNA polymer when the second nucleoside or nucleotide analog is present;
c) incubating the secondary incubated sample with a first labeling reagent comprising an azide group that can undergo a [3+2] cycloaddition reaction with the ethynyl group of the first nucleoside or nucleotide analog and a second labeling reagent that is an antibody that binds to the second nucleoside or nucleotide analog to form a labeled sample; and
d) detecting the labeled sample wherein a level of incorporation of the first nucleoside or nucleotide analog is measured and allows establishment of a baseline rate of the cellular DNA synthesis and a level of incorporation of the second nucleoside or nucleotide analog is measured,
wherein a difference between the level of incorporation of the second nucleoside or nucleotide analog relative to the baseline rate indicates a change in cellular DNA synthesis,
with the proviso that there is no wash step prior to adding the second nucleoside or nucleotide analog.
US Pat. No. 10,139,022

HEATABLE PIPE

Evonik Degussa GmbH, Ess...

1. A heatable pipe, comprising:a layer (layer I) of a moulding compound comprising a east 40 wt. % of the following components:
1) 60 to 99 parts by wt. of a partly aromatic copolyamide containing monomer units obtained from
?) 30 to 90 mol % of a combination of hexamethylenediamine and terephthalic acid, and
?) 70 to 10 mol % of a combination of hexamethylenediamine and a linear aliphatic dicarboxylic acid having 8 to 19 carbon atoms;
wherein the mol % values relate to the sum of ?) and ?) and
wherein not more than 20% of the hexamethylenediamine is optionally replaced by the equivalent amount of another diamine and/or
wherein not more than 20% of the terephthalic acid is optionally replaced by the equivalent amount of another aromatic dicarboxylic acid and/or 1,4-cyclohexanedicarboxylic acid and/or
wherein not more than 20% of the repeating units containing hexamethylenediamine and linear aliphatic dicarboxylic acid are optionally replaced by the equivalent amount of units obtained from a lactam/an ?-aminocarboxylic acid having 6 to 12 carbon atoms,
2) 40 to 1 parts by wt. of an olefinic copolymer as impact modifier,
wherein the parts by wt. of 1) and 2) sum to 100; and
a conductor for electrical current which is embedded between an electrically insulating outer layer and an electrically insulating inner layer.
US Pat. No. 10,138,511

ARRAYS OF MICROPARTICLES AND METHODS OF PREPARATION THEREOF

BioArray Solutions Ltd., ...

1. A method of retaining a population of charged beads in recesses in a surface of a semiconductor comprising depositing a first charged polymer on the surface of the semiconductor, said first charged polymer having a charge of opposite sign to the charged beads, depositing the beads onto the surface of the semiconductor, and depositing a second charged polymer on the surface of the semiconductor, said second charged polymer having a charge of opposite sign to the first charged polymer.
US Pat. No. 10,138,512

NUCLEIC ACID PROCESSING OF A NUCLEIC ACID FRAGMENT WITH A TRIAZOLE LINKAGE

ATDBIO LIMITED, Southham...

1. A method of nucleic acid processing comprising:providing an adapted nucleic acid fragment comprising a nucleic acid fragment linked at its 3?-end to a 3?-adapter molecule by a triazole linkage comprising a 1,2,3-triazole group, wherein the 3?-adapter molecule comprises RNA, DNA, a nucleic acid analogue or combinations thereof;
annealing a primer to the adapted nucleic acid fragment, wherein the primer anneals to a region of the 3?-adapter molecule; and
processing the adapted nucleic acid fragment by transcribing at least a portion of the adapted nucleic acid fragment with reverse transcriptase, wherein said portion of the adapted nucleic acid fragment transcribed with reverse transcriptase comprises said triazole linkage.
US Pat. No. 10,138,513

METHOD AND DEVICE FOR AMPLIFYING AND DETECTING GENE USING GRAPHENE HEATER

ELECTRONICS AND TELECOMMU...

1. A gene amplifying and detecting device, comprising:a gene amplifying chip including a chamber formed therein, the gene amplifying chip having a first sidewall and a second sidewall opposite to the first sidewall;
a reaction solution in the chamber and including a fluorescent material;
a light source adjacent to the first sidewall of the gene amplifying chip;
a light detector located adjacent to the second sidewall of the gene amplifying chip; and
a first graphene heater adjacent to the first sidewall of the gene amplifying chip so as to heat the reaction solution to cause a circulating flow of the reaction solution by convection,
wherein the first graphene heater is positioned between the light source and the chamber to transmit light generated from the light source into the chamber.
US Pat. No. 10,137,234

METHOD FOR STERILIZING BLOOD PURIFIER AND BLOOD PURIFIER PACKAGE

NIPRO CORPORATION, Osaka...

1. A method for sterilizing a blood purifier comprising substantially dried selectively permeable separation membranes as a main component, by exposing said blood purifier to a radioactive ray and/or an electron ray, characterized in that said selectively permeable separation membranes comprise a hydrophobic polymer containing a hydrophilic polymer, said hydrophobic polymer comprises a polysulfone-based polymer, and said blood purifier is sealed in a packaging bag, together with an oxygen scavenger and a humectant or together with an oxygen scavenger capable of releasing a moisture, and is then sterilized in such a sealed state, wherein the relative humidity (RH) in the inner atmosphere of the packaging bag at room temperature is not lower than 50% RH.
US Pat. No. 10,138,516

METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI

Natera, Inc., San Carlos...

1. A method of amplifying target loci of DNA molecules in a nucleic acid sample, the method comprising:(a) contacting the sample and a library of at least 1,000 non-immobilized, non-identical primers that hybridize to at least 1,000 non-identical target loci to produce a reaction mixture in which the concentration of each primer is less than 20 nM; wherein the average length of the DNA molecules is less than 200 base pairs; and wherein a range of melting temperatures of the at least 1000 non-identical primers is less than 10° C.;
(b) subjecting the reaction mixture to PCR conditions to produce amplified products comprising target amplicons; wherein a length of an annealing step of the PCR conditions is greater than 10 minutes; wherein the length of the target amplicons is less than 100 nucleotides; wherein at least 1,000 different target human loci are amplified, and wherein at least 50% of the amplified products comprise target loci.
US Pat. No. 10,137,236

SELF-REGULATING DEVICE FOR MODULATING INFLAMMATION

1. A method of inhibiting tumor necrosis factor-alpha (TNF-?) comprising, providing blood of a patient to an extracorporeal bioreactor, wherein the extracorporeal bioreactor comprises: a compartment comprising cells and a selectively permeable membrane in contact with the cells that does not permit passage of the cells and which permits passage of TNF-? in the blood of the patient, wherein the cells comprise a chimeric gene comprising a response element operably linked to a sequence encoding a soluble TNF-? receptor (sTNFR), in which the response element causes expression of the sTNFR when the cells are contacted with the TNF-? in the blood of the patient; contacting the blood with the selectively permeable membrane, such that the TNF-? in the blood passes through the selectively permeable membrane and sTNFR produced by the cells passes into the blood; and returning the blood to the patient, thereby inhibiting TNF-?.
US Pat. No. 10,138,518

ANNEALING CONTROL PRIMER AND ITS USES

SEEGENE, INC., Seoul (KR...

1. An annealing control primer for improving annealing specificity in nucleic acid amplification, having the formula:5?-Xp—Yq—Zr-3?
wherein Xp represents a 5?-end portion consisting of a pre-selected arbitrary nucleotide sequence substantially not complementary to any site on a template nucleic acid;
wherein Yq represents a regulator portion consisting of 5-15 contiguous universal bases;
wherein Zr represents a 3?-end portion having a hybridizing nucleotide sequence substantially complementary to a site on the template nucleic acid to hybridize therewith;
wherein p, q and r represent the number of nucleotides;
wherein X, Y and Z is deoxyribonucleotide or ribonucleotide;
wherein the base of the deoxyribonucleotide of X is selected from the group consisting of adenine(A), cytosine(C), guanine(G) and thymine(T);
wherein the regulator portion has the lowest Tm in the three portions of the primer, whereby the regulator portion is capable of regulating an annealing portion of the primer in association with annealing temperatures; and
wherein the 5?-end portion is not involved in annealing to the template nucleic acid under conditions that the 3?-end portion anneals to the site on the template nucleic acid such that the 5?-end portion remains unhybridized with the template nucleic acid.
US Pat. No. 10,138,262

REACTIVE MULTI-FUNCTIONAL ADDITIVES FOR COATINGS COMPOSITIONS

Dow Global Technologies L...

1. An acrylic coating composition comprising:(I) from 15 to 45 wt % of a dispersed polymer comprising from 80 to 100 wt % acrylic monomers;
(II) from 15 to 35 wt % titanium dioxide;
(III) from 30 to 70 wt % water; and
(IV) from 1 to 5 wt % of a reactive multi-functional additive, said reactive multi-functional additive comprising:
(i) a multi-functional additive comprising:
(a) from 30 to 50 wt % of a saccharide component having formula (S)m{(CH2CH(R)O)nR1}k, where R1 is hydrogen or —C(O)CH2C(O)CH3, and wherein each group of formula (CH2CH(R)O)nR1 is bonded to an oxygen atom; and
(b) from 50 to 70 wt % of a non-saccharide component having formula P{(CH2CH(R2)O)OR3}p, where R3 is hydrogen or —C(O)CH2C(O)CH3, and wherein each group of formula (CH2CH(R2)O)nR3 is bonded to an oxygen atom;
wherein (CH2CH(R)O)n and (CH2CH(R2)O)n collectively comprise from 30 to 70 wt % of said multi-functional additive; and
wherein n is from 0.5 to 3 and represents a number average; o is from 0.5 to 3 and represents a number average; k is from 4 to 8 and represents a number average; and p is from 2 to 3 and represents a number average; and wherein (S)m is a sucrose unit and R is methyl; and
wherein P is a glycerol unit and R2 is methyl; and
(ii) ammonia or an aliphatic amine having a molecular weight from 60 to 500, wherein the ratio of the number of equivalents of amine to the number of equivalents of acetoacetyl groups is from 0.8:1 to 2:1.
US Pat. No. 10,138,520

DIAGNOSTIC MIRNA MARKERS FOR ALZHEIMER

SIEMENS AKTIENGESELLSCHAF...

1. A method of treating Alzheimer's Disease in a patient in need thereof, said method comprisingadministering an anti-Alzheimer's Disease therapy to the patient, wherein a blood sample from the patient exhibits an expression level value of at least one miRNA selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 78, SEQ ID NO 85, SEQ ID NO 142 and SEQ ID NO 236 compared to a reference expression level value.
US Pat. No. 10,138,264

RECOMBINED MOLECULES AND PREPARATION THEREOF

VALENT TECHNOLOGIES LLC, ...

1. A method for preparation of a recombined molecule from vancomycin comprising the steps of:(a) cleavage of vancomycin with a protease;
(b) splitting the cleaved vancomycin molecules into two separate pools: a first pool and a second pool;
(c) acylating the cleaved vancomycin molecules of the first pool with an acylating agent to acylate all alcohols and amino groups of the cleaved vancomycin molecules of the first pool;
(d) methylating the cleaved vancomycin molecules of the second pool with a methylating agent to methylate all carboxylic acid moieties of the cleaved vancomycin molecules of the second pool;
(e) recombining the acylated cleaved vancomycin molecules of the first pool and the methylated cleaved vancomycin molecules of the second pool by forming peptide bonds with a peptide bond forming agent to afford a recombined molecule from vancomycin comprising acetyl protecting groups and methyl protecting groups; and
(f) removing all acetyl protecting groups and all methyl protecting groups present in the recombined molecule from vancomycin in step (e) by base hydrolysis to produce a recombined molecule from vancomycin.
US Pat. No. 10,138,521

TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND CONDITIONS

Murdoch Childrens Researc...

1. A method of detecting methylation in Fragile X-related Epigenetic Element 2(E) (FREE2(E)) in genomic DNA of a human subject, the method comprising:(a) obtaining isolated genomic DNA from the human subject,
(b) amplifying wholly or partially
FREE2(E) consisting of the nucleotide sequence of SEQ ID NO:49 or a modified SEQ ID NO:49 in which methylated cytosine(s) in SEQ ID NO:49 are converted to uracil(s) using a first primer complementary to a first region of SEQ ID NO:49 or to the modified SEQ ID NO:49 sequence in which methylated cytosine(s) have been converted to uracil(s) and a second primer complementary to a second region of SEQ ID NO:49 or to the modified SEQ ID NO:49 sequence in which methylated cytosine(s) have been converted to uracil(s), wherein the second primer is non-overlapping with the first primer; and
(c) detecting methylation in the wholly or partially amplified FREE2(E).
US Pat. No. 10,138,522

IDENTIFICATION OF CATTLE AT RISK OF HIGH ALTITUDE PULMONARY HYPERTENSION

VANDERBILT UNIVERSITY, N...

7. A method of breeding cattle, comprising,a) subjecting a nucleic acid-containing sample from a head of cattle to nucleic acid sequence analysis;
b) analyzing the nucleotide present at positions 1816 and/or 1828 in exon 12 of the bovine EPAS1 gene;
c) detecting a G allele at position 1816 in exon 12 of the bovine EPAS1 gene and/or a G allele present at position 1828 in exon 12 of the bovine EPAS1 gene; and
d) breeding the head of cattle with a G allele at position 1816 in exon 12 of the bovine EPAS1 gene and/or a G allele present at position 1828 in exon 12 of the bovine EPAS1 gene.
US Pat. No. 10,138,266

METHOD OF CUTTING OUT RNA OLIGONUCLEOTIDE

Nitto Denko Corporation, ...

1. A method of cutting out an RNA oligonucleotide chemically synthesized on a universal support from the support, comprisinga step of bringing the support carrying the RNA oligonucleotide in contact with an aqueous solution containing alkylamine and 10-60 mM monovalent inorganic salt.
US Pat. No. 10,138,523

CANCER BIOMARKER AND DIAGNOSTIC

1. A method for monitoring colorectal cancer in a subject, wherein the method comprises:(i) measuring the level of ATP11B and S100A11 gene expression or the quantity of protein or peptides resulting from ATP11B and S100A11 gene translation in samples from the subject from two or more successive time points;
(ii) comparing the level or quantity of both markers between the samples as measured in (i);
(iii) finding a deviation of at least about 40% (about 1.4-fold or more)_or no deviation of the quantity of both markers between the samples as compared in (ii); and
(iv) attributing the finding of deviation or no deviation to a change in the colorectal cancer in the subject between the two or more successive time points.
US Pat. No. 10,138,268

PEPTIDE FRAGMENT CONDENSATION AND CYCLISATION USING A SUBTILISIN VARIANT WITH IMPROVED SYNTHESIS OVER HYDROLYSIS RATIO

ENZYPEP B.V., Geleen (NL...

1. A method for enzymatically synthesizing an (oligo)peptide, comprising:coupling (a) an (oligo)peptide C-terminal ester or thioester and (b) an (oligo)peptide nucleophile having an N-terminally unprotected amine,
wherein the coupling is carried out in a fluid comprising water, and
wherein the coupling is catalyzed by a subtilisin BPN? variant or mutant, said variant or mutant comprising mutations, said mutations comprising:
a deletion of the calcium binding domain corresponding to amino acid corresponding to positions 75-83; and
a mutation at the amino acid position corresponding to S221, the mutation corresponding to S221C or S221selenocysteine;
wherein the amino acid positions are defined based upon the numbering of the amino acid sequence of SEQ ID NO:2, and wherein the subtilisin BPN? variant or mutant has enzymatic activity.
US Pat. No. 10,138,526

MOLECULAR MARKERS ASSOCIATED WITH STEM CANKER RESISTANCE IN SOYBEAN

Monsanto Technology LLC, ...

1. A method of producing a population of soybean plants that comprises a genotype associated with a stem canker resistance phenotype, the method comprising:(i) genotyping a first population of soybean plants, wherein the first population contains at least one allele associated with the stem canker resistance phenotype, wherein the allele is located in at least one stem canker resistance marker locus, wherein the stem canker resistance marker locus is in a linkage group Dlb genomic region , and wherein said genomic region is flanked by and including:
a) loci NGMAX008369670 and NGMAX008369689;
b) loci NGMAX008369675 and NGMAX008369689;
c) loci NGMAX008369673 and NGMAX008369689;
d) loci NGMAX008369676 and NGMAX008369689;
e) loci NGMAX008369683 and NGMAX008369689;
f) loci NGMAX008369675 and NGMAX008369686;
g) loci NGMAX008369673 and NGMAX008369686;
h) loci NGMAX008369676 and NGMAX008369686; or,
i) loci NGMAX008369683 and NGMAX008369686,
(ii) selecting from said first population of soybean plants based upon said genotyping one or more soybean plants comprising the at least one allele associated with a stem canker resistance phenotype; and
(iii) producing offspring from the one or more selected soybean plants of the first population of soybean plants by crossing the selected soybean plant with another soybean plant,
thereby producing a second population of soybean plants comprising a genotype associated with a stem canker resistant phenotype.
US Pat. No. 10,138,527

METHOD FOR MONITORING DIFFERENTIATION INTO CARDIAC MUSCLE CELLS

OLYMPUS CORPORATION, Tok...

1. A method for monitoring differentiation into cardiac muscle cells comprising:introducing, into cells, a reporter gene of luminescent protein configured to vary in luminescence intensity according to an expression of a myocardial differentiation marker gene, wherein the reporter gene is a cTnT gene expression specific luminescent vector, wherein the cells are stem cells or cardiac progenitor cells;
keeping, in an alive state, the cells into which the reporter gene of luminescent protein were introduced;
acquiring a luminescence image as a still image by imaging light emitted from the cells in a light shielding state;
acquiring sequential images with illuminating the cells, the step of acquiring the sequential images comprising acquiring a bright-field image of the cells;
associating biological information obtained from the sequential images with biological information obtained from the still image;
conducting a motion analysis based on the bright-field image, wherein the motion analysis is conducted by use of an image correlation method;
analyzing beating of the cells by the motion analysis;
analyzing expression of the myocardial differentiation marker gene based on the luminescence image; and
assessing a relationship between the beating and the expression.
US Pat. No. 10,138,271

NATIVE AND AGONIST CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN

The United States of Amer...

1. A method of enhancing an immune response against a MUC1-expressing cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising(i) a poxvirus vector comprising a nucleic acid encoding a peptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 29, and SEQ ID NO: 32, or
(ii) a liposome comprising a peptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 29, and SEQ ID NO: 32,
wherein the immune response in the subject is enhanced.
US Pat. No. 10,138,016

COATED BOX WITH ANTI-GREASY FINGERPRINT COATING

FC Meyer Packaging LLC, ...

1. A container, comprising:a paperboard having creases that fold the paperboard into a box shape that has exterior facing surfaces that face away from each other and interior facing surfaces that face each other;
a water-based barrier coating on portions of the exterior facing surfaces of the paperboard to coat the portions and that is configured to prevent staining from grease and water of the portions of the exterior facing surfaces of the paperboard that are coated, the water-based barrier coating having 35% to 45% solid suspension and being configured to exhibit a hydrophobic effect to deposits of water and oil, the exterior facing surfaces also having uncoated portions that are uncoated and thereby lack the water-based barrier coating, the water-based barrier coating including a primer coat layer applied on the paperboard with the paperboard remaining open to absorb moisture even though the primer coat is applied on the paperboard, an overcoat layer on the primer coat layer and having a higher volume of a same coating material than that of the primer coat layer, the primer coat and the overcoat together providing a surface tension necessary to seal the paperboard against absorbing fluid and resist staining from greasy fingerprints; and
a water-based adhesive adhering the uncoated portions of the exterior facing surfaces to portions of the interior facing surfaces that are in alignment therewith.
US Pat. No. 10,138,272

MATRIPTASE AND U-PLASMINOGEN ACTIVATOR SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOF

CytomX Therapeutics, Inc....

1. An isolated polypeptide comprising a cleavable moiety (CM), wherein the CM comprises the amino acid sequence of SEQ ID NO: 363, wherein the CM is a substrate for a protease, wherein the isolated polypeptide comprises at least one moiety (M) selected from the group consisting of a moiety that is located amino (N) terminally to the CM (MN), a moiety that is located carboxyl (C) terminally to the CM (MC), and combinations thereof, and wherein the MN or MC is selected from the group consisting of an antibody or antigen binding fragment thereof (AB), a therapeutic agent, an antineoplastic agent, a toxic agent, a drug, and a detectable label.
US Pat. No. 10,141,607

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

GS Yuasa International Lt...

1. A nonaqueous electrolyte secondary battery comprising a nonaqueous electrolyte,wherein the nonaqueous electrolyte contains 2-fluorotoluene and lithium difluorophosphate,
the content of the 2-fluorotoluene is 4 mass % or more and 8 mass % or less per the nonaqueous electrolyte, and
the content of the lithium difluorophosphate is 1 mass % or more and 6 mass % or less per the nonaqueous electrolyte.
US Pat. No. 10,138,273

PEPTIDE LIGANDS FOR HEPATIC STELLATE CELLS

The Curators of the Unive...

1. A composition comprising:a polypeptide comprising an amino acid sequence having the amino acid sequence of SEQ ID NO: 6, wherein the polypeptide binds to at least a portion of an insulin-like growth factor 2 receptor (IGF2R) extracellular domain; and
at least one of an anti-fibrotic agent, an anti-cancer agent, or a proapoptotic agent.
US Pat. No. 10,138,533

METHOD FOR PRODUCING HIGH-PURITY CALCIUM

1. High-purity calcium having a purity, excluding gas components, Sr, and Ba, of 4N5 or higher and containing silicon as an impurity in an amount of: less than 0.05 ppm, produced by a process comprising the steps of:charging calcium starting material having a purity, excluding the gas components, of 4N or less into a crucible of a sublimation vessel;
performing first sublimation purification by heating at 750° C. to 800° C. so that calcium is sublimated and deposits (evaporates) onto the inner side wall of the sublimation vessel;
recovering the calcium purified by the first sublimation purification;
charging the calcium into a crucible of a sublimation vessel again;
performing second sublimation purification by heating at 750° C. to 800° C. so that the calcium is sublimated and deposits (evaporates) onto the inner side wall of the sublimation vessel; and
recovering the calcium having a purity, excluding gas components, Sr, and Ba, of 4N5 or higher and containing silicon as an impurity in an amount of less than 0.05 ppm.
US Pat. No. 10,138,277

VIRUS-LIKE PARTICLES AND METHODS OF USE

The United States of Amer...

1. An isolated polynucleotide encoding an altered viral protein selected from the group consisting of:a. an alphavirus E2 protein comprising at least one alteration, relative to the wild-type amino acid sequence, at one or more amino acid locations corresponding to at least one amino acid position selected from the group consisting of H170, K200, K233, K234, R251, and H256 of Chikungunya E2 protein; and
b. an alphavirus capsid protein comprising at least one alteration, relative to the wild type sequence, in the Nuclear Localization Signal (NLS);
wherein the altered protein is capable of self-assembling into a virus like particle (VLP); and,
wherein the at least one alteration enhances production of VLPs.
US Pat. No. 10,138,534

NICKEL ALLOY

ROLLS-ROYCE plc, London ...

1. A nickel alloy having the following composition (in atomic percent unless otherwise stated): between 5.75 and 6.75 Al, between 4.5 and 5.8 Ti, between 0.5 and 1.3 Ta, up to 1% Nb, between 13.5% and 16% Cr, between 22and 27% Co, between 0.1 and 0.3% C, between 0.05 and 0.2% B, between 0.02 and 0.07% Zr, up to 1.1% W, between 1.4 and 2.85% Mo, up to 1% Fe, up to 0.7% Mn, up to 1% Si, up to 0.15% Hf, and up to 0.05% Mg; the balance being Ni and incidental impurities.
US Pat. No. 10,138,278

FLUOROGEN ACTIVATING AND SHIFTING TAG (FAST)

CENTRE NATIONAL DE LA REC...

1. A a functional photoactive yellow protein (PYP) polypeptide comprising the sequence of SEQ ID NO: 48, or a sequence having at least 70% identity with the sequence of SEQ ID NO: 48, wherein said sequence further comprises one or more amino acid substitutions in the amino acid region at position 94-101 with reference to SEQ ID NO: 48, one of said substitutions being a proline at position 97 with reference to SEQ ID NO: 48, and wherein said polypeptide binds reversibly a fluorogenic chromophore with:a KD ranging from about 0.05 to about 10 ?M when measured at a temperature of about 25° C.; and/or
a koff ranging from about 1 to about 50 s?1 when measured at a temperature of about 25° C.; and/or
a kon ranging from about 0.1×107 to about 50×107 M?1s?1 when measured at a temperature of about 25° C.
US Pat. No. 10,138,279

COMPOSITIONS AND METHODS FOR BACILLUS ANTHRACIS VACCINATION

Regents of the University...

1. A method of inducing an immune response to Bacillus anthracis (B. anthracis) in a subject comprising intranasally administering an immunogenic composition comprising:A) a nanoemulsion, wherein the nanoemulsion comprises:
1. oil;
2. water;
3. ethanol;
4. a polysorbate surfactant selected from the group consisting of polyoxyethylene sorbitan monooleate and polyoxyethylene sorbitan monolaurate; and
5. cetylpyridinium chloride (CPC); and
B) recombinant protective antigen (rPA) of B. anthracis to the subject, wherein the administering generates a B. anthracis-specific immune response comprising generation of a serum anthrax lethal toxin (LeTx)-specific neutralizing antibody titer that is at least 10 fold greater than the serum LeTx-specific neutralizing antibody titer generated in a control subject administered an equal amount of rPA suspended in saline.
US Pat. No. 10,138,280

POLYPEPTIDES TARGETING GLYCOSYLATED MUC2 PROTEINS, METHODS OF SYNTHESIS, THEIR NUCLEIC ACIDS AND USES THEREOF

Institut Pasteur, Paris ...

1. An isolated nucleic acid molecule that comprises an open reading frame that encodes a polypeptide consisting of:a) SEQ ID NO: 3 having an additional cysteine residue at the N-terminus,
b) a fragment of SEQ ID NO: 3, wherein the fragment has an additional cysteine residue at the N-terminus, and wherein the fragment has a length of at least 20 contiguous amino acid residues,
c) a variant of SEQ ID NO: 3, wherein the variant has an additional cysteine residue at the N-terminus and has at least 85% identity with SEQ ID NO: 3, or
d) a variant of a fragment of SEQ ID NO: 3, wherein the variant of the fragment has an additional cysteine residue at the N-terminus, has a length of at least 20 contiguous amino acid residues, and has at least 85% identity with the fragment of SEQ ID NO: 3.
US Pat. No. 10,137,514

ABRASIVE ARTICLE AND METHOD OF FORMING

SAINT-GOBAIN ABRASIVES, I...

1. An abrasive article comprising:a substrate comprising an elongated body;
a plurality of discrete tacking regions overlying the substrate and defining gap regions between each of the discrete tacking regions of the plurality of discrete tacking regions;
abrasive particles overlying the plurality of discrete tacking regions;
a plurality of discrete formations overlying the substrate and spaced apart from the plurality of discrete tacking regions and the abrasive particles; and
a bonding layer overlying the plurality of discrete tacking regions, wherein at least a portion of the bonding layer is directly bonded to the substrate.
US Pat. No. 10,138,284

NON-STANDARD INSULIN ANALOGUES

Case Western Reserve Univ...

1. An insulin analogue comprising the insulin B-chain polypeptide containing a Cyclohexanylalanine substitution at a position corresponding to position B24 of wild type insulin and a glutamic acid substitution at a position corresponding to position B29 of wild type insulin; wherein optionally the insulin analogue comprises a lysine substitution at a position corresponding to position B3 of wild type insulin.
US Pat. No. 10,138,285

DIAGNOSIS OF A NEUROAUTOIMMUNE DISEASE COMPRISING MEASURING AUTOANTIBODIES TO FLOTILLIN1 AND/OR FLOTILLIN2

EUROIMMUN MEDIZINISCHE LA...

1. A method for detecting the presence of an autoantibody in a subject, comprising:obtaining a sample from a subject;
exposing a complex comprising 1) flotillin1 or a variant thereof and 2) flotillin2 or a variant thereof, which is immobilized on a solid carrier, to the sample from the subject; and
detecting whether the autoantibody is present in the sample by detecting the binding between the autoantibody and the complex.
US Pat. No. 10,138,286

METHODS AND COMPOSITIONS FOR INHIBITING THE EFFECTS OF AMYLOID BETA OLIGOMERS

The Board of Trustees of ...

1. A composition comprising a LILRB2 polypeptide consisting of the first two Ig-like domains of LILRB2, which are residues 24-223 of SEQ ID NO: 3; and an Fc domain.
US Pat. No. 10,138,290

PROCESS FOR PROTEIN PRODUCTION

Novo Nordisk Healthcare A...

1. A large-scale, continuous perfusion process for producing a haemostasis protein, comprisingproviding a cell culture in suspension in a bioreactor, wherein the bioreactor is in fluid communication with a filter module, wherein the bioreactor volume is at least 500 L, and wherein the filter module mesh size is from about 0.1 ?m to about 2.9 ?m;
providing a dissolved oxygen concentration in the suspension of around 20% to 100%; and
flowing the cell culture suspension across the filter module in an alternating tangential flow, in order to separate haemostasis protein produced by the cell culture from the cells; and
culturing the cells to a target cell density below 80×106 cell s/ml.
US Pat. No. 10,138,292

CELL CULTURE MEDIUM

BIOLAMINA AB, Sundbyberg...

1. A system for maintaining human pluripotent stem cells, comprising:a chemically defined and xeno-free cell culture medium comprising from greater than zero to 3.9 ng/mL of basic fibroblast growth factor (bFGF), wherein the cell culture medium does not contain (1) insulin or an insulin substitute, and does not contain (2) transferrin or a transferrin substitute; and
a container having a substrate thereon, the substrate containing laminin-521 or laminin-511 for providing support to the human pluripotent stem cells.
US Pat. No. 10,138,293

BIVALENT, BISPECIFIC ANTIBODIES

HOFFMANN-LA ROCHE, INC., ...

1. A bivalent, bispecific antibody comprising two pairs of light chains and heavy chains, each light chain comprising a variable region and a constant region, each heavy chain comprising a variable region and a constant region, wherein:a) the light chain and heavy chain of the first of the two pairs specifically bind to a first antigen, wherein the light chain comprises the following domains in N-terminal to C-terminal direction VL, CL and the heavy chain comprises the following domains in N-terminal to C-terminal direction VH, CH1, CH2, CH3; and
b) the light chain and heavy chain of the second of the two pairs specifically bind to a second antigen, wherein the light chain comprises the following domains in N-terminal to C-terminal direction VH, CL and the heavy chain comprises the following domains in N-terminal to C-terminal direction VL, CH1, CH2, CH3.
US Pat. No. 10,138,038

ANTIMICROBIAL DETECTABLE CABLE TIE

1. A cable tie comprising:a body having a composition wherein the composition comprises a base plastic, an antimicrobial additive, and a detectable additive selected from a detectable metal additive, an X-ray detectable additive and combinations thereof, and wherein the antimicrobial additive includes silver ion complex and at least one selected from the group consisting of copper ion complex, polychloro phenoxy phenol derivative, quaternary ammonium compound, and zinc pyrithione derivative, and
a head having a barb comprising an antimicrobial metallic barb material,
wherein the body and the head are integrally connected, and wherein the antimicrobial metallic barb material comprises a copper alloy selected from the group consisting of C28000, C11000, C51000, C70600, C26000, and C75200.
US Pat. No. 10,138,294

TEMPERATURE SHIFT FOR HIGH YIELD EXPRESSION OF POLYPEPTIDES IN YEAST AND OTHER TRANSFORMED CELLS

ALDERBIO HOLDINGS LLC, L...

1. A method of producing a recombinant multi-subunit complex in yeast cells, comprising:(a) culturing at a first temperature yeast cells comprising one or more genes that encode said multi-subunit complex; and
(b) culturing said yeast cells at a second temperature and allowing said yeast cells to produce said multi-subunit complex;
wherein said first temperature is between 27.5° C. and 28.5° C., and said second temperature is between 30° C. and 31° C.,
wherein said method increases the yield of said protein and/or decreases the relative abundance of one or more product-associated variants relative to the same method effected without a difference between said first temperature and said second temperature, and
wherein the promoter or promoters which regulate the transcription of the one or more genes that encode said multi-subunit complex are not temperature inducible.
US Pat. No. 10,139,320

COMPOSITION FOR PROCESSING HISTOLOGICAL, POSTMORTEM, CYTOLOGICAL SAMPLES

Giacomo Madau, Cagliari ...

1. A method to process a biological sample, the method comprisingtreating the biological sample with a composition to process the biological sample, the composition comprising
at least one 2-ethylhexyl ester selected from the group consisting of 2-ethylhexyl benzoate, 2-ethylhexyl palmitate, 2-ethylhexyl cocoate, 2-ethylhexyl stearate, and 2-ethylhexyl acetate; and
ethyl alcohol and/or isopropyl alcohol,
wherein the at least one 2-ethylhexyl ester is in a concentration ranging from 30% to 70%, with respect to a total volume of the composition, the ethyl alcohol is in a concentration ranging from 20% to 60% with respect to the total volume of the composition and the isopropyl alcohol is in a concentration ranging from 10% to 30% with respect to the total volume of the composition.
US Pat. No. 10,139,321

MUCOLYTIC TABLET FOR A SAMPLE COLLECTION DEVICE

Alpha-Tec Systems, Inc., ...

1. A mucolytic tablet for a sample collection device, comprising:(i) 15% to 65% by weight of N-acetyl L-cysteine (NALC);
(ii) 6% to 30% by weight of a buffering agent;
(iii) 10% to 14% by weight of a water soluble anti-adherent; and
(iv) 2% to 10% by weight of at least one water soluble chelating and lubricating agent,
wherein the mucolytic tablet solubilizes in a resuspension buffer.
US Pat. No. 10,138,298

ANTI-IL-2 ANTIBODIES AND COMPOSITIONS AND USES THEREOF

The Regents of the Univer...

1. An isolated antibody or antigen-binding portion thereof that specifically binds human IL-2, said antibody comprising: a heavy chain complementarity determining region 1 (HCDR1) comprising SEQ ID NO:127, a heavy chain complementarity determining region 2 (HCDR2) comprising SEQ ID NO:130, a heavy chain complementarity determining region 3 (HCDR3) comprising SEQ ID NO:132, a light chain complementarity determining region 1 (LCDR1) comprising SEQ ID NO:133, a light chain complementarity determining region 2 (LCDR2) comprising SEQ ID NO:134, and a light chain complementarity determining region 3 (LCDR3) comprising SEQ ID NO:135.
US Pat. No. 10,138,299

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

Bristol-Myers Squibb Comp...

1. A method of treating a tumor in a human subject in need thereof, comprising administering to the subject about 10 mg/kg of an anti-PD-L1 antibody every 2 weeks, wherein the anti-PD-L1 antibody is administered intravenously over 60 minutes infusion;wherein the tumor is derived from a bladder cancer of; and wherein the tumor is refractory to a platinum based chemotherapy.
US Pat. No. 10,138,300

ANTI-VEGFR ANTIBODY AND USES THEREOF

DEVELOPMENT CENTER FOR BI...

1. An antibody or antigen-binding fragment thereof that specifically binds to an epitope in human vascular endothelial growth factor receptor 2 (VEGFR-2) or a fragment thereof; wherein the human vascular endothelial growth factor receptor 2 has the amino acid sequence of SEQ ID NO: 1, and the epitope comprises:the serine residue at position 711, the lysine residue at position 716, the aspartic acid residue at position 717, and the arginine residues at positions 725 and 726 of SEQ ID NO: 1; which antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) of a heavy chain variable region and complementarity determining regions of a light chain variable region, wherein the complementarity determining regions of the heavy chain variable region comprises CDRH1, CDRH2 and CDRH3 regions, and the complementarity determining regions of the light chain variable region comprises CDRL1, CDRL2 and CDRL3 regions, and the CDRH1 region comprises the amino acid sequence of SEQ ID NO: 4; the CDRH2 region comprises the amino acid sequence of SEQ ID NO: 5; the CDRH3 region comprises the amino acid sequence of SEQ ID NO: 6; the CDRL1 region comprises the amino acid sequence of SEQ ID NO: 7; the CDRL2 region comprises the amino acid sequence of SEQ ID NO: 8; and the CDRL3 region comprises the amino acid sequence of SEQ ID NO: 9.
US Pat. No. 10,138,301

MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2

GALAXY BIOTECH, LLC, Cup...

1. An isolated monoclonal antibody (mAb) that binds human fibroblast growth factor receptor 2 isoform IIIb (FGFR2 IIIb) comprising a light chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 24-34, 50-56, and 89-97 of SEQ ID NO. 1 and comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 31-35, 50-66 and 99-103 of SEQ ID NO:4.
US Pat. No. 10,138,558

PRETREATMENT AGENT FOR ELECTROLESS PLATING, AND PRETREATMENT AND PRODUCTION OF PRINTED WIRING BOARD USING SAME

1. A pretreatment agent for electroless plating, comprising:a silane coupling agent;
a surfactant; and
ethylene-based glycol butyl ethers of formula: C4H9—(OC2H4)nOH where n is an integer of 1 to 4, and/or propylene-based glycol butyl ethers of formula: C4H9—(OC3H6)nOH where n is an integer of 1 to 4.
US Pat. No. 10,137,534

BONDING WIRE FOR SEMICONDUCTOR DEVICE

Nippon Micrometal Corpora...

1. A bonding wire for a semiconductor device, the bonding wire comprising:a Cu alloy core material; and
a Pd coating layer formed on a surface of the Cu alloy core material, wherein
the bonding wire contains at least one element selected from Ni, Zn, Rh, Ir, and Pt,
a concentration of the elements in total relative to the entire wire is 0.03% by mass or more and 2% by mass or less, or
the bonding wire contains In, a concentration of In is 0.07% by mass or more and 2% by mass or less relative to the entire wire,
when measuring crystal orientations on a cross-section of the core material in a direction perpendicular to a wire axis of the bonding wire, a crystal orientation <100> angled at 15 degrees or less to the wire axis direction has a proportion of 50% or more among crystal orientations in the wire axis direction, and
an average crystal grain size in the cross-section of the core material in the direction perpendicular to the wire axis of the bonding wire is 0.9 ?m or more and 1.3 ?m or less.
US Pat. No. 10,138,303

HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM

RINAT NEUROSCIENCE CORP.,...

1. A heterodimeric protein comprising:a hinge region comprising a first immunoglobulin-like hinge polypeptide and a second immunoglobulin-like hinge polypeptide which interact together to form a dimeric hinge interface, wherein electrostatic interactions between one or more charged amino acids within the hinge interface favor interaction between the first and second hinge polypeptides over interaction between two first hinge polypeptides or two second hinge polypeptides, thereby promoting heterodimer formation over homodimer formation, wherein the hinge region is a human IgG1 hinge region, wherein the first hinge polypeptide comprises at least one amino acid modification relative to a wild-type IgG hinge region; wherein the wild-type amino acid in the first hinge polypeptide is replaced with an amino acid having an opposite charge to the corresponding amino acid in the second hinge polypeptide, wherein the amino acid modification in the hinge region comprises Asp221 as shown at FIG. 6A, and further comprising an immunoglobulin-like CH3 region comprising a first CH3 polypeptide fused to the first hinge polypeptide and a second CH3 polypeptide fused to the second hinge polypeptide, wherein the first CH3 polypeptide and the second CH3 polypeptide comprise at least one amino acid modification relative to a wild-type IgG1 CH3 region sequence at a position selected from the group consisting of Tyr349, Leu368, Phe405, and Lys409 (EU numbering scheme) as shown at FIG. 10.
US Pat. No. 10,138,560

METHODS AND SYSTEMS UTILIZING A BORON-CONTAINING CORROSION INHIBITOR FOR PROTECTION OF TITANIUM SURFACES

Halliburton Energy Servic...

1. A method comprising:contacting a metal surface consisting of titanium or a titanium alloy with a corrosion inhibitor composition comprising a boron-containing compound, wherein the boron-containing compound comprises a boron-alkanolamine complex;
interacting the metal surface with a fluid phase comprising hydrofluoric acid or acidic fluoride ions; and
suppressing corrosion of the metal surface by the hydrofluoric acid or acidic fluoride ions with the boron-containing compound.
US Pat. No. 10,137,280

SYSTEM AND METHOD FOR TREATMENT OF HEMORRHAGIC STROKE

InCube Labs, LLC, San Jo...

1. A method for treating a cerebral aneurysm, the method comprising:advancing a microcatheter having a delivery lumen to the site of the aneurysm;
delivering a carrier containing a first agent and a second agent to the aneurysm through the delivery lumen of the microcatheter so as to at least partially fill a sac of the aneurysm; wherein the first agent comprises an anti-inflammatory agent and the second agent comprises a member of the transforming growth factor-? family; and
controllably releasing the first and second agents from the carrier to the site of the aneurysm,
wherein the carrier comprises a first gel component including the first agent and a second gel component including the second agent,
wherein the first gel component has a first viscosity selected to release the first agent at a first rate of release, and
wherein the second gel component has a second viscosity different from the first viscosity, the second viscosity being selected to release the second agent at a second rate of release slower than the first rate of release.
US Pat. No. 10,138,304

METHODS FOR INCREASING THE EXTRACTABLE RUBBER CONTENT OF NON-HEVEA PLANT MATTER

Bridgestone Corporation, ...

1. A method for increasing the extractable rubber content of non-Hevea plant matter without unduly increasing the extractable resin content comprising:utilizing a quantity of chopped non-Hevea plant matter having an average length of ½? to 4? and a maximum moisture content of 15 weight % and subjecting the chopped non-Hevea plant matter to at least one of
hammer milling utilizing a screen size of less than ½? and greater than or equal to 3/16?; and
roller milling with corrugated rolls having no more than 8 corrugations per inch,
thereby producing a quantity of milled non-Hevea plant matter having a maximum moisture content of 15 weight %, an extractable rubber content at least 30% higher than the pre-milled chopped non-Hevea plant matter and an extractable resin content of no more than 3 times the extractable rubber content.
US Pat. No. 10,138,306

METHACRYLIC ACID PRODUCTION METHOD

University of Georgia Res...

1. A method of producing methacrylic acid comprising reacting a substrate with a palladium nitrate catalyst comprising a hydrotalcite under conditions sufficient to produce methacrylic acid in a single step, wherein the substrate is selected from the group consisting of 2-hydroxyisobutyric acid or salts thereof, itaconic acid or salts thereof, citric acid or salts thereof, citramalic acid or salts thereof, and combinations thereof.
US Pat. No. 10,138,308

CATALYST COMPONENT FOR THE PREPARATION OF NUCLEATED POLYOLEFINS

BOREALIS AG, (AT)

1. A process of obtaining a catalyst composition containing a catalyst component, the process comprising:a1) providing a solution of at least a Group 2 metal alkoxy compound (Ax) being the reaction product of a Group 2 metal compound (MC) and a monohydric alcohol (A) comprising in addition to the hydroxyl moiety at least one ether moiety optionally in an organic liquid reaction medium; or
a2) providing a solution of at least a Group 2 metal alkoxy compound (Ax?) being the reaction product of a Group 2 metal compound (MC) and an alcohol mixture of the monohydric alcohol (A) and a monohydric alcohol (B) of formula ROH, optionally in an organic liquid reaction medium; or
a3) providing a solution of a mixture of the Group 2 metal alkoxy compound (Ax) and a Group 2 metal alkoxy compound (Bx) being the reaction product of a Group 2 metal compound (MC) and the monohydric alcohol (B), optionally in an organic liquid reaction medium; or
a4) providing a solution of Group 2 metal alkoxy compound of formula M(OR1)n(OR2)mX2-n-m or mixture of Group 2 alkoxides M(OR1)n?X2-n? and M(OR2)m?X2-m?, where M is Group 2 metal, X is halogen, R1 and R2 are different alkyl groups of C2 to C16 carbon atoms, and 0 b) adding said solution from step a) to at least one compound (TC) of a transition metal of Group 4 to 6, and
c) obtaining the solid catalyst component particles,
d) washing said solidified particles,
e) recovering the solidified particles of the olefin polymerisation catalyst component, wherein an electron donor is added at any step prior to step c) and is a non-phthalic internal electron donor, and
wherein the catalyst component is further modified by a polymeric nucleating agent comprising vinyl compound units;
wherein the catalyst component is washed in step d) at least three times with at least one toluene and at least one TiCl4 washing step and 1 to 3 further washing steps with an aromatic and/or aliphatic hydrocarbon selected from toluene, heptane or pentane; and
wherein internal donor is added to either the toluene wash step and/or to the TiCl4 wash step, whereby the amount of donor added to the washing steps is in the range of 10 to 60 wt % of the total amount of donor used in catalyst preparation steps a) to d).
US Pat. No. 10,138,566

SEALING ANODIZED ALUMINUM USING A LOW-TEMPERATURE NICKEL-FREE PROCESS

MacDermid Acumen, Inc., ...

1. A method for sealing an anodized aluminum or anodized aluminum alloy surface comprising:(i) contacting the anodized surface with a sealing composition comprising a source of lithium ions, a source of fluoride ions, and a complexing agent, followed by;
(ii) contacting the anodized surface with a passivation composition wherein the passivation composition comprises a source of metal ions and a complexing agent;
wherein the surface of the anodized aluminum or anodized aluminum alloy becomes corrosion resistant, and
wherein the temperature of the passivation composition is less than 80° C.
US Pat. No. 10,138,310

PREPARATION OF LLDPE RESINS AND FILMS HAVING LOW GELS

Equistar Chemicals, LP, ...

1. A process for making a linear low density polyethylene resin comprising the steps of:copolymerizing ethylene with a comonomer selected from 1-butene and 1-hexene, and wherein the comonomer used in an amount within the range of 5-10% by weight of ethylene to produce a linear low density polyethylene;
wherein the copolymerizing step is performed in the presence of hydrogen, an inert gas selected from nitrogen and carbon dioxide, and
a Ziegler-Natta catalyst comprising:
a MgCl2 support,
a Ti(IV) complex, and
an internal electron donor comprising a cyclic ether; and
wherein Ziegler-Natta catalyst is formed by first contacting the MgCl2 support with the Ti(IV) complex to form an intermediate product, and the intermediate product is then contacted with the internal electron donor to produce the Ziegler-Natta catalyst;
wherein the Ziegler-Natta catalyst has an Mg/Ti molar ratio greater than or equal to 7, and an internal electron donor/Ti molar ratio between 5 and 20; and
wherein the linear low density polyethylene resin has a gel defect area less than or equal to 25 ppm;
wherein the catalyst is characterized by an X-ray diffraction spectrum which, in the range of 2? diffraction angles between 5.0° and 20.0°, has at least three main diffraction peaks: 2? of 7.2±0.2°, 11.5±0.2°, and 14.5±0.2°; and
wherein the peak at 2? of 7.2±0.2° is most intense and the peak at 11.5±0.2° has an intensity less than 90% of the intensity of the peak at 2? of 7.2±0.2°.
US Pat. No. 10,138,569

WELD CLEANING FLUID

Ensitech IP PTY LLP, Emu...

1. A stainless steel cleaning composition, comprising:an aqueous solution having a pH that is approximately neutral, said aqueous solution having from more than 30% to 60% by weight of a phosphoric acid salt, and having up to 20% by weight of a salt of a polyaminocarboxylic acid as a sequestering or chelating agent,
wherein said acid salt is selected to induce passivation of stainless steel through oxidation of chromium atoms within the stainless steel, and
all optional components of said composition are selected to be chemically unreactive with, and non-chemically-bonding to, metals.
US Pat. No. 10,138,314

RUBBER GRAFT COPOLYMER, AND THERMOPLASTIC RESIN COMPOSITION CONTAINING RUBBER GRAFT COPOLYMER

KANEKA CORPORATION, Osak...

1. A rubber graft copolymer comprising a core layer containing a rubber polymer and a shell layer grafted on the core layer satisfying all of the following (1) to (7):(1) the rubber graft copolymer polymerized under the presence of an alkaline metal salt of a phosphate compound,
(2) the rubber graft copolymer obtained by contacting a solution containing an alkaline earth metal chloride to a latex containing the rubber graft copolymer obtained by the emulsion polymerization to coagulate the copolymer,
(3) the rubber graft copolymer in which the phosphate compound remains as an alkaline earth metal salt in the rubber graft copolymer, the remaining amount of the alkaline earth metal salt of the phosphate compound is 400 ppm or more and 3000 ppm or less as an alkaline earth metal on a mass basis,
(4) the rubber graft copolymer obtained by polymerizing at conditions of pH of 5.0 to 9.0,
(5) the rubber graft copolymer in which the rubber polymer is a polybutadiene or a poly (butadiene-styrene),
(6) a concentration of monomers used in the polymerization of the shell layer is (i) 60 to 80% by mass of methyl methacrylate and 20 to 40% by mass of styrene, or (ii) 70 to 99% by mass of methyl methacrylate and 1 to 30% by mass of butylacrylate, or (iii) 30 to 40% by mass of glycidyl methacrylate, 45 to 55% by mass of methylmethacrylate, and 5 to 25% by mass of styrene, per 100% by mass of monomers constituting the shell layer, and
(7) the alkaline metal salt of the phosphate compound is polyoxyalkylene alkyl phenyl ether phosphate salt or polyoxyalkylene alkyl ether phosphate salt.
US Pat. No. 10,138,316

AMPHIPHILIC BRANCHED POLYDIORGANOSILOXANE MACROMERS

Novartis AG, Basel (CH)

1. An amphiphilic branched polydiorganosiloxane macromer, comprising:(1) at least first one polydiorganosiloxane polymer chain having two terminal methacryloyl groups; and
(2) at least one first hydrophilic chain;
(3) at least one second hydrophilic polymer chain; and
(4) at least one second polydiorganosiloxane polymer chain at least one end of which is covalently connected to the second hydrophilic polymer chain,
wherein the first and second polydiorganosiloxane chains are derived from an ?,?-dimethacryloyl-terminated polydiorganosiloxane vinylic crosslinker comprising one or more ATRP-containing siloxane units having one substituent having an ATRP initiator,
wherein the first hydrophilic chain is anchored covalently onto one single ATRP-containing siloxane unit of the first or second polydiorganosiloxane chain at one of the two ends of the first hydrophilic polymer chain and has one first terminal group at the other one of the two ends of the first hydrophilic polymer chain,
wherein the second hydrophilic polymer chain is (a) anchored covalently onto one single ATRP-containing siloxane unit of the first polydiorganosiloxane chain at one of the two ends of the second hydrophilic polymer chain, (b) has one second terminal group at the other one of the two ends of the second hydrophilic polymer chain, and (c) is covalently connected to covalently connected to one of the two ends of the second polydiorganosiloxane chain,
wherein the first and second terminal groups independent of each other are (meth)acryloxy group, (meth)acryloxy-C2-C4 alkoxy group, (meth)acrylamido-C2-C4 alkoxy group, (meth)acryloxy-C2-C4 alkylamino group, (meth)acrylamido-C2-C4 alkylamino group, C1-C6 substituted or unsubstituted alkoxy group, C2-C6 substituted or unsubstituted alkanoyloxy group, or C1-C6 substituted or unsubstituted alkylamino group, wherein the first and second hydrophilic polymer chains are composed of monomeric units of at least one hydrophilic vinylic monomer selected from the group consisting of (meth)acrylamide, N,N-dimethyl (meth)acrylamide, dimethylaminoethyl (meth)acrylate, dimethylaminoethyl (meth)acrylamide, N-vinyl-2-pyrrolidone, N-vinyl-N-methyl isopropylamide, N-vinyl-N-methyl acetamide, N-vinyl formamide, N-vinyl acetamide, N-vinyl isopropylamide, N-vinyl-N-methyl acetamide, hydroxyethyl (meth)acrylate, hydroxyethyl (meth)acrylamide, hydroxypropyl (meth)acrylamide, glycerol methacrylate (GMA), polyethylene glycol (meth)acrylate, polyethylene glycol C1-C4-alkyl ether (meth)acrylate having a number average molecular weight of up to 1500, and mixtures thereof.
US Pat. No. 10,138,576

BIOCOMPATIBLE HYDROPHILIC COMPOSITIONS

3M INNOVATIVE PROPERTIES ...

1. A nonwoven web of fibers, wherein the fibers comprise a blend comprising:at least one thermoplastic aliphatic polyester;
an alkyl, alkenyl, aralkyl, or alkaryl anionic surfactant incorporated in the polyester; wherein the surfactant is selected from the group consisting of alkyl sulfate, alkenyl sulfate, alkaryl sulfate, aralkyl sulfate, alkylalkoxylated sulfate, alkyl sulfonate, alkenyl sulfonate, alkaryl sulfonate, aralkyl sulfonate, alkylalkoxylated sulfonate, alkyl phosphonate, alkenyl phosphonate, alkaryl phosphonate, aralkyl phosphonate, alkyl phosphate, alkenyl phosphate, alkaryl phosphate, aralkyl phosphate, alkyl alkoxylated phosphate, di(C8-C18) sulfosuccinate salts, C8-C22 alkyl sarcosinate salts, C8-C22 alkyl lactylate salts, and combinations thereof; wherein the surfactant is present in a concentration sufficient to make the nonwoven web durably hydrophilic and absorbent and instantaneously wettable; and
a surfactant carrier;
wherein the fibers are 20 micrometers or less in diameter;
wherein the surfactant is soluble in the carrier at greater than 10% by weight such that the surfactant and carrier form a visually transparent solution in a 1-cm path length glass vial when heated to 150° C.
US Pat. No. 10,138,320

COMB-BLOCK HIGH DENSITY POLYETHYLENES AND METHODS OF MAKING THEM

ExxonMobil Chemical Paten...

1. A process for making a polyethylene composition comprising:contacting, at a temperature of at least 100° C., ethylene with a first salan catalyst precursor and an activator to form branched vinyl/vinylidene-terminated high density polyethylene (“bVT-HDPE”) having a number average molecular weight (Mn) of at least 5,000 g/mole;
contacting, at a temperature of at least 100° C., the bVT-HDPE with ethylene and a second metallocene catalyst precursor and an activator to form a comb-block HDPE; and
isolating a polyethylene composition.
US Pat. No. 10,138,577

POLYPHENYLENE SULFIDE FIBERS, AND MANUFACTURING METHOD THEREFOR

Toray Industries, Inc., ...

1. A poly(phenylene sulfide) fiber containing 1-10% by weight of a poly(phenylene sulfide) oligomer having a weight-average molecular weight of 5,000 or less, having a difference between a cold crystallization heat quantity (?Hc) and a crystal melting heat quantity (?Hm) during temperature rising in DSC, ?Hm??Hc, of 25 J/g or larger, and having an elongation of less than 40% and a strength of 3.0 cN/dtex or higher.
US Pat. No. 10,139,345

MAGNETIC AND RAMAN BASED METHOD FOR PROCESS CONTROL DURING FABRICATION OF CARBON NANOTUBE BASED STRUCTURES

THE UNITED STATES OF AMER...

13. A method for process control during fabrication of carbon nanotube structures, the method comprising:providing a carbon nanotube starting material;
forming the composite structure with the carbon nanotube starting material under one or more fabrication process parameters; and
monitoring a magnetic property of the composite structure while forming the composite structure.
US Pat. No. 10,138,321

PROCESS FOR PRODUCTION OF OXYMETHYLENE COPOLYMER

MITSUBISHI GAS CHEMICAL C...

1. A method for producing an oxymethylene copolymer, comprising a polymerization step for cationically polymerizing trioxane and a comonomer at a polymerization temperature of from 135 to 300° C. in the presence of at least one salt of a protonic acid having a molecular weight of 1,000 or less, and at least one polymerization initiator selected from the group consisting of protonic acids having a molecular weight of 1,000 or less, protonic acid anhydrides having a molecular weight of 1,000 or less, and protonic acid ester compounds having a molecular weight of 1,000 or less, wherein the trioxane and comonomer used in the polymerization step contain metal components in a total concentration of 300 ppb by mass or less.